<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02974855</url>
  </required_header>
  <id_info>
    <org_study_id>B7841002</org_study_id>
    <secondary_id>2016-001885-27</secondary_id>
    <nct_id>NCT02974855</nct_id>
  </id_info>
  <brief_title>PF-06741086 Multiple Dose Study in Severe Hemophilia</brief_title>
  <official_title>A MULTICENTER, OPEN-LABEL, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF SUBCUTANEOUS OR INTRAVENOUS PF-06741086 IN SUBJECTS WITH SEVERE HEMOPHILIA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety, tolerability, pharmacokinetics,&#xD;
      pharmacodynamics and efficacy of multiple subcutaneous and/or intravenous doses of&#xD;
      PF-06741086 in subjects with severe hemophilia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 8, 2017</start_date>
  <completion_date type="Actual">December 3, 2018</completion_date>
  <primary_completion_date type="Actual">December 3, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Study Day 1 to Day 113 Visit</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. AEs included both SAEs and non-serious AEs. TEAEs were AEs occurred following the start of treatment or AEs increasing in severity during treatment. Severe TEAEs were TEAEs that interfered significantly with participants' usual function. Treatment-related TEAEs were determined by the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Discontinued From Study Due to TEAEs</measure>
    <time_frame>Study Day 1 to Day 113 Visit</time_frame>
    <description>An AE was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Laboratory Findings-Hematology</measure>
    <time_frame>Baseline to Study Day 113 Visit</time_frame>
    <description>Hematology evaluation included: hemoglobin, hematocrit, erythrocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes. Predefined criteria for hemoglobin and hematocrit: &lt;0.8*lower limit of normal (LLN) or &lt;0.8*Baseline(Baseline &lt;1.0*LLN); for platelets: &lt;100,000*10^3/mm^3 or &lt;= 0.77*Baseline (Baseline &lt;1.0*LLN).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Laboratory Findings-Clinical Chemistry</measure>
    <time_frame>Baseline to Study Day 113</time_frame>
    <description>Clinical chemistry evaluation included bilirubin, direct and indirect bilirubin, aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, alkaline phosphatase, protein, albumin, urea nitrogen, creatinine, urate, triglycerides, sodium, potassium, chloride, calcium, bicarbonate, glucose, creatine kinase, troponin I, cholesterol and fibrinogen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Laboratory Findings-Urinalysis</measure>
    <time_frame>Baseline to Study Day 113 Visit</time_frame>
    <description>Urinalysis included: pH, urine glucose, ketones, urine protein, urine hemoglobin, urobilinogen, urine bilirubin, nitrite, leukocyte esterase, urine erythrocytes, urine leukocytes and bacteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline for Globulin by Dose Cohort</measure>
    <time_frame>Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.</time_frame>
    <description>Blood samples were obtained to determine globulin level in serum, total globulin was derived as total protein other than albumin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline for Prothrombin International Normalized Ratio (PT/INR) by Dose Cohort</measure>
    <time_frame>Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.</time_frame>
    <description>Blood samples were obtained to evaluate this ratio. The prothrombin time (PT) is a test that helps evaluate your ability to appropriately form blood clots. The international normalized ratio (INR) is a calculation based on results of a PT that is used to monitor individuals who are being treated with the blood-thinning medication (anticoagulant) warfarin (Coumadin®).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline for Activated Partial Thromboplastin Time (aPTT) by Dose Cohort</measure>
    <time_frame>Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.</time_frame>
    <description>The activated partial thromboplastin time (aPTT) is a screening test that helps evaluate a person's ability to appropriately form blood clots. It measures the number of seconds it takes for a clot to form in a sample of blood after substances (reagents) are added. Blood sample were obtained to evaluate aPTT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline for Fibrinogen by Dose Cohort</measure>
    <time_frame>Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.</time_frame>
    <description>Fibrinogen is a protein, specifically a clotting factor (factor I), that is essential for proper blood clot formation. Blood samples were obtained to evaluate the amount of fibrinogen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline for Antithrombin III by Dose Cohort</measure>
    <time_frame>Baseline, Study Day 8, 15, 22 and 29.</time_frame>
    <description>Antithrombin (AT) is a protein produced by the liver that helps regulate blood clot formation (i.e., a naturally-occurring mild blood thinner). Blood samples were collected to measure the activity (function) and the amount (quantity) of antithrombin in an individual's blood is used to evaluate the person for excessive blood clotting.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline for Troponin I by Dose Cohort</measure>
    <time_frame>Baseline, Study Day 8, 15, 22, 29, 57 and 85.</time_frame>
    <description>Blood samples were collected to measure the level of cardiac-specific troponin I in the blood to help detect heart injury.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Vital Signs Data Meeting Pre-specified Criteria</measure>
    <time_frame>Baseline to Study Day 113 Visit</time_frame>
    <description>Criteria for potentially clinically important findings in vital signs data were defined as: 1) supine systolic blood pressure (BP): value &lt;90 mm Hg or change &gt;=30 mm Hg increase; 2) Supine diastolic BP: value &lt;50 mm Hg or change &gt;=20 mm Hg increase; 3) Supine pulse rate: value &lt;40 beats/min or &gt;120 beats/min.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Electrocardiogram (ECG) Change Meeting Pre-specified Criteria</measure>
    <time_frame>Baseline to Study Day 29 Visit.</time_frame>
    <description>Criteria for potentially clinically important changes in ECG were defined as: PR interval baseline &gt;200 msec and increase of &gt;=25%; PR interval baseline &lt;=200 msec and increase of &gt;=50%; QRS interval increase of &gt;=50%. Only the number of participants meeting pre-defined criteria was reported below.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Physical Examination Findings</measure>
    <time_frame>Baseline to Study Day 113 Visit</time_frame>
    <description>Physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. Clinical significance was judged by the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Infusion and Injection Site Reactions</measure>
    <time_frame>Baseline to Study Day 113 Visit</time_frame>
    <description>Infusion and injection site reactions included: injection site bruising, injection site erythema, injection site haemorrhage, injection site induration, injection site pain, injection site pruritus, injection site swelling and injection site warmth. Grade of severity was defined as follows: Mild: Transient or mild discomfort (&lt; 48 hours); no medical intervention/therapy required. Moderate: Mild to moderate limitation in activity - some assistance may be needed; no or minimal medical intervention/therapy required. Severe: Marked limitation in activity, some assistance usually required; medical intervention/therapy required, hospitalizations possible.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized Bleeding Rate (ABR)</measure>
    <time_frame>Pre-treatment: within 6 months prior to study enrollment; On-study: Day 1 to 9 days after the last dose (Day 78)</time_frame>
    <description>Pre-treatment ABR = number of bleeding episodes within 6 months prior to study enrollment (total number of bleeding episodes in hemophilia history CRF) × 2; On-study ABR = number of bleeding episodes occurred within 9 days after the last dose / ([last dose date + 9 - first dose date + 1] / 365.25) The historical On Demand group was constructed using the following internal Pfizer studies: ReFacto AF 3082B2-4432 (B1831004), BeneFIX B1821010, and BeneFIX 3090A1-400 (B1821004). Participants who were on On Demand treatment in B1831004, as well as data from the On Demand period in B1821004 and B1821010 were used to construct the historical On Demand group. The resulting dataset were further filtered to match the key inclusion/exclusion criteria of Study B7841002 based on age and factor activity (18 &lt;=age &lt;=65 and factor activity &lt;=1%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PF-06741086 Concentrations</measure>
    <time_frame>pre-dose on Study Day 1, 24hours (h), 72h post Study Day 1 dosing, pre-dose on Study Day 8, 15 and 22, pre-dose on Study Day 29, 24h, 96h post Study Day 29 dosing, pre-dose on Study Day 57, 168h, 840h post Study Day 57 dosing</time_frame>
    <description>Plasma PF-06741086 concentrations were analyzed using a validated, sensitive and specific electrochemiluminescence (ECL) method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PF-06741086</measure>
    <time_frame>Pre-dose on Day 1, 24 and 96 hours post Day 1 dosing</time_frame>
    <description>AUClast was calculated by linear/Log trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of PF-06741086</measure>
    <time_frame>Pre-dose on Day 1, 24 and 96 hours post Day 1 dosing, pre-dose on Day 29, 24 and 96 hours post Day 29 dosing</time_frame>
    <description>Cmax was observed directly from data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lowest Concentration Observed During the Dosing Interval (Cmin) of PF-06741086</measure>
    <time_frame>Pre-dose on Day 1, 24 and 96 hours post Day 1 dosing, pre-dose on Day 29, 24 and 96 hours post Day 29 dosing</time_frame>
    <description>Cmin was observed directly from data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) of PF-06741086</measure>
    <time_frame>Pre-dose on Day 1, 24 and 96 hours post Day 1 dosing, pre-dose on Day 29, 24 and 96 hours post Day 29 dosing</time_frame>
    <description>Tmax was observed directly from data as time of first occurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration-time Curve Over the Dosing Interval Tau (AUCtau) of PF-06741086</measure>
    <time_frame>Pre-dose on Day 29, 24 and 96 hours post Day 29 dosing</time_frame>
    <description>The dosing interval tau was 1 week. AUCtau was obtained by linear/log trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance After Oral Dose (CL/F) of PF-06741086</measure>
    <time_frame>Pre-dose on Day 29, 24 and 96 hours post Day 29 dosing</time_frame>
    <description>CL/F was calculated by dose/AUCtau.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Tissue Factor Pathway Inhibitor (TFPI)</measure>
    <time_frame>Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113</time_frame>
    <description>Total amount of tissue factor pathway inhibitor (TFPI) (bound and unbound) in plasma. TFPI is a protease inhibitor which acts as an antagonist of the extrinsic coagulation pathway via inhibition of tissue factor activated coagulation factor VII (FVIIa) and activated factor X (FXa). Human plasma samples were analyzed for total TFPI concentrations using a validated, sensitive and specific high-performance liquid chromatography tandem mass spectrometric method (LC-MS/MS). Mixed model repeated measures (MMRM) was used to analyze the change from baseline on TFPI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Thrombin Generation (TGA) Lag Time</measure>
    <time_frame>Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113</time_frame>
    <description>An ex vivo pharmacodynamic measure of thrombin generation (initiation of thrombin generation), the lag time is the time needed to form the first traces of thrombin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Thrombin Generation (TGA) Peak</measure>
    <time_frame>Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113</time_frame>
    <description>An ex vivo pharmacodynamic measure of thrombin generation (initiation of thrombin generation). The peak represents the highest thrombin concentration that can be generated. There may be patients who reach the peak faster or slower than others and this may represent hyper- or hypocoagulability, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Endogenous Thrombin Generation (TGA) Potential</measure>
    <time_frame>Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113</time_frame>
    <description>An ex vivo pharmacodynamic measure of thrombin generation. The endogenous TGA potential represents the total amount of active thrombin formed during thrombin generation and the peak height the maximal amount of thrombin formed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Prothrombin Fragments 1 + 2</measure>
    <time_frame>Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113</time_frame>
    <description>An in vivo pharmacodynamic measure of thrombin generation (prothrombin cleavage). Prothrombin fragment 1+2 (F 1+2) is the amino terminus fragment of the prothrombin molecule. It is a polypeptide with a half-life of approximately 90 minutes. F 1+2 is released from prothrombin when prothrombin is converted to thrombin by the prothrombinase complex.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in D-Dimer</measure>
    <time_frame>Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113</time_frame>
    <description>An in vivo pharmacodynamic measure of thrombin generation (fibrin degradation). D-dimer is a fibrin degradation product, a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis. D-dimer is one of the protein fragments produced when a blood clot gets dissolved in the body. It is normally undetectable or detectable at a very low level unless the body is forming and breaking down blood clots. Then, its level in the blood can significantly rise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Dilute Prothrombin Time</measure>
    <time_frame>Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113</time_frame>
    <description>An ex vivo pharmacodynamic measure of thrombin generation (via extrinsic pathway). Clotting time is measured using a dilute prothrombin time reagent consisting of a unique formulation of relipidated recombinant tissue factor and calcium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Tested Positive for Anti-PF-06741086 Antibody (ADA)</measure>
    <time_frame>Baseline up to Study Day 113</time_frame>
    <description>Human plasma ADA samples were analyzed for the detection of anti PF-06741086 antibodies by using semi-quantitative electrochemiluminescence (ECL) method. The criterion for positive result of ADA samples was ADA titer &gt;=1.53. Treatment induced are negative prior to dosing and become positive during/after dosing. Treatment boosted are positive prior to dosing but titer increases during/after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Tested Positive for Neutralizing Antibody (NAb)</measure>
    <time_frame>Baseline up to Study Day 113</time_frame>
    <description>Human plasma NAb samples were analyzed for the presence or absence of NAb to PF-06741086 using semi-quantitative electrochemiluminescence (ECL) method. Treatment induced are negative prior to dosing and become positive during/after dosing. Treatment boosted are positive prior to dosing but titer increases during/after dosing.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Hemophilia A or B</condition>
  <arm_group>
    <arm_group_label>PF-06741086 (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06741086 (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06741086 (Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06741086 (Cohort 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06741086</intervention_name>
    <description>PF-06741086 subcutaneous (SC) injection</description>
    <arm_group_label>PF-06741086 (Cohort 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06741086</intervention_name>
    <description>PF-06741086 SC injection</description>
    <arm_group_label>PF-06741086 (Cohort 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06741086</intervention_name>
    <description>PF-06741086 SC injection</description>
    <arm_group_label>PF-06741086 (Cohort 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06741086</intervention_name>
    <description>PF-06741086 SC injection</description>
    <arm_group_label>PF-06741086 (Cohort 4)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Severe hemophilia A or B (Factor VIII or Factor IX activity ≤ 1%), including patients&#xD;
             with inhibitors to Factor VIII or Factor IX&#xD;
&#xD;
          -  Episodic (on-demand) treatment regimen prior to screening&#xD;
&#xD;
          -  At least 6 acute bleeding episodes during the 6-month period prior to screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known coronary artery, thrombotic, or ischemic disease&#xD;
&#xD;
          -  Currently receiving treatment for acute bleeding episodes with APCC and cannot&#xD;
             substitute treatment with rFVIIa&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC Denver Hemophilia and Thrombosis Center - Pharmacy</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Denver Hemophilia and Thrombosis Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacy</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Sotero del Rio</name>
      <address>
        <city>Santiago</city>
        <zip>8207257</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinicki bolnicki centar Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Pharma (Pty) Ltd</name>
      <address>
        <city>Port Elizabeth</city>
        <state>Eastern CAPE</state>
        <zip>6001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haemophilia Comprehensive Care Centre</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitatsSpital Zurich, Klinik fur Hamatologie</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>Croatia</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B7841002</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 23, 2016</study_first_submitted>
  <study_first_submitted_qc>November 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2016</study_first_posted>
  <results_first_submitted>November 15, 2019</results_first_submitted>
  <results_first_submitted_qc>November 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 4, 2019</results_first_posted>
  <last_update_submitted>November 15, 2019</last_update_submitted>
  <last_update_submitted_qc>November 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hemophilia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 2, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT02974855/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT02974855/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 27 participants were enrolled in the study and assigned to 1 of 4 cohorts. Only 26 participants received the study treatment and 1 participant withdrew after randomization but prior to dosing.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
          <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
        </group>
        <group group_id="P2">
          <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
          <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
        </group>
        <group group_id="P3">
          <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
          <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
        </group>
        <group group_id="P4">
          <title>PF-06741086 300 mg SC QW Inhibitor</title>
          <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline analysis population included all participants who received at least 1 dose of study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
          <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
        </group>
        <group group_id="B2">
          <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
          <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
        </group>
        <group group_id="B3">
          <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
          <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
        </group>
        <group group_id="B4">
          <title>PF-06741086 300 mg SC QW Inhibitor</title>
          <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.9" spread="8.17"/>
                    <measurement group_id="B2" value="28.7" spread="8.31"/>
                    <measurement group_id="B3" value="41.7" spread="15.87"/>
                    <measurement group_id="B4" value="44.1" spread="9.44"/>
                    <measurement group_id="B5" value="36.7" spread="12.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs)</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. AEs included both SAEs and non-serious AEs. TEAEs were AEs occurred following the start of treatment or AEs increasing in severity during treatment. Severe TEAEs were TEAEs that interfered significantly with participants' usual function. Treatment-related TEAEs were determined by the investigator.</description>
        <time_frame>Study Day 1 to Day 113 Visit</time_frame>
        <population>The analysis population included all participants who received at least 1 dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
          <group group_id="O6">
            <title>Total</title>
            <description>The total group combined participants from all PF-06741086 cohorts in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs)</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. AEs included both SAEs and non-serious AEs. TEAEs were AEs occurred following the start of treatment or AEs increasing in severity during treatment. Severe TEAEs were TEAEs that interfered significantly with participants' usual function. Treatment-related TEAEs were determined by the investigator.</description>
          <population>The analysis population included all participants who received at least 1 dose of investigational product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All-causalities TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All-causalities serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All-causalities Grade 3 or 4 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related Grade 3 or 4 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Discontinued From Study Due to TEAEs</title>
        <description>An AE was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.</description>
        <time_frame>Study Day 1 to Day 113 Visit</time_frame>
        <population>The analysis population included all participants who received at least 1 dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
          <group group_id="O6">
            <title>Total</title>
            <description>The total group combined participants from all PF-06741086 cohorts in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Discontinued From Study Due to TEAEs</title>
          <description>An AE was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.</description>
          <population>The analysis population included all participants who received at least 1 dose of investigational product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All-causalities TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Laboratory Findings-Hematology</title>
        <description>Hematology evaluation included: hemoglobin, hematocrit, erythrocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes. Predefined criteria for hemoglobin and hematocrit: &lt;0.8*lower limit of normal (LLN) or &lt;0.8*Baseline(Baseline &lt;1.0*LLN); for platelets: &lt;100,000*10^3/mm^3 or &lt;= 0.77*Baseline (Baseline &lt;1.0*LLN).</description>
        <time_frame>Baseline to Study Day 113 Visit</time_frame>
        <population>This analysis population included all participants who received at least 1 dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
          <group group_id="O6">
            <title>Total</title>
            <description>The total group combined participants from all PF-06741086 cohorts in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Laboratory Findings-Hematology</title>
          <description>Hematology evaluation included: hemoglobin, hematocrit, erythrocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes. Predefined criteria for hemoglobin and hematocrit: &lt;0.8*lower limit of normal (LLN) or &lt;0.8*Baseline(Baseline &lt;1.0*LLN); for platelets: &lt;100,000*10^3/mm^3 or &lt;= 0.77*Baseline (Baseline &lt;1.0*LLN).</description>
          <population>This analysis population included all participants who received at least 1 dose of investigational product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin meeting pre-defined criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit meeting pre-defined criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocytes &lt;0.8*LLN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets meeting pre-defined criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes &lt;0.6*LLN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes &gt;1.5*upper limit of normal (ULN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes &lt;0.8*LLN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes &gt;1.2*ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils &lt;0.8*LLN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils &gt;1.2*ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils &gt;1.2*ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils &gt;1.2*ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes &gt;1.2*ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Laboratory Findings-Clinical Chemistry</title>
        <description>Clinical chemistry evaluation included bilirubin, direct and indirect bilirubin, aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, alkaline phosphatase, protein, albumin, urea nitrogen, creatinine, urate, triglycerides, sodium, potassium, chloride, calcium, bicarbonate, glucose, creatine kinase, troponin I, cholesterol and fibrinogen.</description>
        <time_frame>Baseline to Study Day 113</time_frame>
        <population>This analysis population included all participants who received at least 1 dose of investigational product. Number analyzed refers to number of participants evaluable for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
          <group group_id="O6">
            <title>Total</title>
            <description>The total group combined participants from all PF-06741086 cohorts in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Laboratory Findings-Clinical Chemistry</title>
          <description>Clinical chemistry evaluation included bilirubin, direct and indirect bilirubin, aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, alkaline phosphatase, protein, albumin, urea nitrogen, creatinine, urate, triglycerides, sodium, potassium, chloride, calcium, bicarbonate, glucose, creatine kinase, troponin I, cholesterol and fibrinogen.</description>
          <population>This analysis population included all participants who received at least 1 dose of investigational product. Number analyzed refers to number of participants evaluable for specified rows.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bilirubin &gt;1.5*ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Bilirubin &gt;1.5*ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indirect Bilirubin &gt;1.5*ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase &gt;3.0*ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase &gt;3.0*ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma Glutamyl Transferase &gt;3.0*ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein &lt;0.8*LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein &gt;1.2*ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin &lt;0.8*LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin &gt;1.2*ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea Nitrogen &gt;1.3*ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine &gt;1.3*ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urate &gt;1.2*ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides &gt;1.3*ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium &lt;0.95*LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium &gt;1.05*ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium &lt;0.9*LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium &gt;1.1*ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride &lt;0.9*LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride &gt;1.1*ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium &lt;0.9*LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium &gt;1.1*ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate &lt;0.9*LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate &gt;1.1*ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose &lt;0.6*LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose &gt;1.5*ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase &gt;2.0*ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Troponin I &gt;1.0*ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol &gt;1.3*ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibrinogen &lt;=0.5*LLN or &lt;=0.5*baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Laboratory Findings-Urinalysis</title>
        <description>Urinalysis included: pH, urine glucose, ketones, urine protein, urine hemoglobin, urobilinogen, urine bilirubin, nitrite, leukocyte esterase, urine erythrocytes, urine leukocytes and bacteria.</description>
        <time_frame>Baseline to Study Day 113 Visit</time_frame>
        <population>This analysis population included all participants who received at least 1 dose of investigational product. Number analyzed refers to number of participants evaluable for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
          <group group_id="O6">
            <title>Total</title>
            <description>The total group combined participants from all PF-06741086 cohorts in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Laboratory Findings-Urinalysis</title>
          <description>Urinalysis included: pH, urine glucose, ketones, urine protein, urine hemoglobin, urobilinogen, urine bilirubin, nitrite, leukocyte esterase, urine erythrocytes, urine leukocytes and bacteria.</description>
          <population>This analysis population included all participants who received at least 1 dose of investigational product. Number analyzed refers to number of participants evaluable for specified rows.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pH (Scalar) &lt;4.5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pH (Scalar) &gt;8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine glucose &gt;=1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones (Scalar) &gt;=1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine protein &gt;=1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine hemoglobin (Scalar) &gt;=1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urobilinogen &gt;=1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine bilirubin (Scalar) &gt;=1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nitrite (Scalar) &gt;=1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocyte esterase (Scalar) &gt;=1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine erythrocytes (/HPF) &gt;=20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine leukocytes (/HPF) &gt;=20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bacteria (/HPF) &gt;20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline for Globulin by Dose Cohort</title>
        <description>Blood samples were obtained to determine globulin level in serum, total globulin was derived as total protein other than albumin.</description>
        <time_frame>Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.</time_frame>
        <population>This analysis population included all participants randomized and who had received at least 1 dose of randomized treatment. Number analyzed refers to number of participants evaluable for specified rows of time points.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
          <group group_id="O6">
            <title>Total</title>
            <description>The total group combined participants from all PF-06741086 cohorts in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline for Globulin by Dose Cohort</title>
          <description>Blood samples were obtained to determine globulin level in serum, total globulin was derived as total protein other than albumin.</description>
          <population>This analysis population included all participants randomized and who had received at least 1 dose of randomized treatment. Number analyzed refers to number of participants evaluable for specified rows of time points.</population>
          <units>gram/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Globulin, Change at Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="3.04"/>
                    <measurement group_id="O2" value="-1.7" spread="3.93"/>
                    <measurement group_id="O3" value="-1.3" spread="2.73"/>
                    <measurement group_id="O4" value="0.4" spread="2.51"/>
                    <measurement group_id="O5" value="0.1" spread="2.70"/>
                    <measurement group_id="O6" value="-0.7" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Globulin, Change at Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="2.06"/>
                    <measurement group_id="O2" value="-0.8" spread="2.32"/>
                    <measurement group_id="O3" value="-1.3" spread="2.50"/>
                    <measurement group_id="O4" value="-1.3" spread="3.35"/>
                    <measurement group_id="O5" value="-1.0" spread="2.69"/>
                    <measurement group_id="O6" value="-1.0" spread="2.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Globulin, Study Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="2.82"/>
                    <measurement group_id="O2" value="-0.5" spread="1.52"/>
                    <measurement group_id="O3" value="-1.5" spread="3.08"/>
                    <measurement group_id="O4" value="-0.6" spread="4.12"/>
                    <measurement group_id="O5" value="-1.1" spread="3.43"/>
                    <measurement group_id="O6" value="-1.0" spread="2.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Globulin, Change at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="3.27"/>
                    <measurement group_id="O2" value="-0.3" spread="3.08"/>
                    <measurement group_id="O3" value="0.2" spread="1.10"/>
                    <measurement group_id="O4" value="-1.3" spread="2.75"/>
                    <measurement group_id="O5" value="-0.8" spread="2.91"/>
                    <measurement group_id="O6" value="-0.5" spread="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Globulin, Change at Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="3.72"/>
                    <measurement group_id="O2" value="1.8" spread="2.99"/>
                    <measurement group_id="O3" value="-0.3" spread="1.63"/>
                    <measurement group_id="O4" value="-0.7" spread="2.94"/>
                    <measurement group_id="O5" value="0.0" spread="3.28"/>
                    <measurement group_id="O6" value="0.4" spread="2.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Globulin, Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="3.15"/>
                    <measurement group_id="O2" value="-1.4" spread="4.77"/>
                    <measurement group_id="O3" value="-0.5" spread="3.02"/>
                    <measurement group_id="O4" value="1.0" spread="2.61"/>
                    <measurement group_id="O5" value="1.2" spread="2.79"/>
                    <measurement group_id="O6" value="0.2" spread="3.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Globulin, Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="3.15"/>
                    <measurement group_id="O2" value="-1.2" spread="4.67"/>
                    <measurement group_id="O3" value="0.5" spread="2.65"/>
                    <measurement group_id="O4" value="-0.8" spread="3.06"/>
                    <measurement group_id="O5" value="-0.5" spread="2.99"/>
                    <measurement group_id="O6" value="-0.5" spread="3.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline for Prothrombin International Normalized Ratio (PT/INR) by Dose Cohort</title>
        <description>Blood samples were obtained to evaluate this ratio. The prothrombin time (PT) is a test that helps evaluate your ability to appropriately form blood clots. The international normalized ratio (INR) is a calculation based on results of a PT that is used to monitor individuals who are being treated with the blood-thinning medication (anticoagulant) warfarin (Coumadin®).</description>
        <time_frame>Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.</time_frame>
        <population>This analysis population included all participants randomized and who had received at least 1 dose of randomized treatment. Number analyzed refers to number of participants evaluable for specified rows of time points.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
          <group group_id="O6">
            <title>Total</title>
            <description>The total group combined participants from all PF-06741086 cohorts in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline for Prothrombin International Normalized Ratio (PT/INR) by Dose Cohort</title>
          <description>Blood samples were obtained to evaluate this ratio. The prothrombin time (PT) is a test that helps evaluate your ability to appropriately form blood clots. The international normalized ratio (INR) is a calculation based on results of a PT that is used to monitor individuals who are being treated with the blood-thinning medication (anticoagulant) warfarin (Coumadin®).</description>
          <population>This analysis population included all participants randomized and who had received at least 1 dose of randomized treatment. Number analyzed refers to number of participants evaluable for specified rows of time points.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PT/INR, Change at Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.049"/>
                    <measurement group_id="O2" value="-0.02" spread="0.041"/>
                    <measurement group_id="O3" value="0.05" spread="0.138"/>
                    <measurement group_id="O4" value="0.03" spread="0.138"/>
                    <measurement group_id="O5" value="0.00" spread="0.104"/>
                    <measurement group_id="O6" value="0.01" spread="0.102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT/INR, Change at Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.076"/>
                    <measurement group_id="O2" value="0.00" spread="0.063"/>
                    <measurement group_id="O3" value="0.02" spread="0.041"/>
                    <measurement group_id="O4" value="0.00" spread="0.082"/>
                    <measurement group_id="O5" value="0.01" spread="0.077"/>
                    <measurement group_id="O6" value="0.01" spread="0.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT/INR, Change at Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.095"/>
                    <measurement group_id="O2" value="0.00" spread="0.063"/>
                    <measurement group_id="O3" value="-0.02" spread="0.041"/>
                    <measurement group_id="O4" value="-0.01" spread="0.069"/>
                    <measurement group_id="O5" value="0.01" spread="0.083"/>
                    <measurement group_id="O6" value="0.00" spread="0.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT/INR, Change at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.082"/>
                    <measurement group_id="O2" value="-0.02" spread="0.041"/>
                    <measurement group_id="O3" value="0.00" spread="0.063"/>
                    <measurement group_id="O4" value="0.00" spread="0.115"/>
                    <measurement group_id="O5" value="0.02" spread="0.099"/>
                    <measurement group_id="O6" value="0.00" spread="0.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT/INR, Change at Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.126"/>
                    <measurement group_id="O2" value="-0.03" spread="0.052"/>
                    <measurement group_id="O3" value="0.00" spread="0.063"/>
                    <measurement group_id="O4" value="-0.02" spread="0.075"/>
                    <measurement group_id="O5" value="-0.01" spread="0.100"/>
                    <measurement group_id="O6" value="-0.01" spread="0.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT/INR, Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.107"/>
                    <measurement group_id="O2" value="0.04" spread="0.152"/>
                    <measurement group_id="O3" value="-0.02" spread="0.075"/>
                    <measurement group_id="O4" value="-0.03" spread="0.082"/>
                    <measurement group_id="O5" value="-0.02" spread="0.093"/>
                    <measurement group_id="O6" value="-0.01" spread="0.102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT/INR, Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.127"/>
                    <measurement group_id="O2" value="-0.03" spread="0.052"/>
                    <measurement group_id="O3" value="-0.05" spread="0.058"/>
                    <measurement group_id="O4" value="0.07" spread="0.052"/>
                    <measurement group_id="O5" value="0.06" spread="0.096"/>
                    <measurement group_id="O6" value="0.02" spread="0.094"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline for Activated Partial Thromboplastin Time (aPTT) by Dose Cohort</title>
        <description>The activated partial thromboplastin time (aPTT) is a screening test that helps evaluate a person's ability to appropriately form blood clots. It measures the number of seconds it takes for a clot to form in a sample of blood after substances (reagents) are added. Blood sample were obtained to evaluate aPTT.</description>
        <time_frame>Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.</time_frame>
        <population>This analysis population included all participants randomized and who had received at least 1 dose of randomized treatment. Number analyzed refers to number of participants evaluable for specified rows of time points.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
          <group group_id="O6">
            <title>Total</title>
            <description>The total group combined participants from all PF-06741086 cohorts in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline for Activated Partial Thromboplastin Time (aPTT) by Dose Cohort</title>
          <description>The activated partial thromboplastin time (aPTT) is a screening test that helps evaluate a person's ability to appropriately form blood clots. It measures the number of seconds it takes for a clot to form in a sample of blood after substances (reagents) are added. Blood sample were obtained to evaluate aPTT.</description>
          <population>This analysis population included all participants randomized and who had received at least 1 dose of randomized treatment. Number analyzed refers to number of participants evaluable for specified rows of time points.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>aPTT, Change at Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.49" spread="17.017"/>
                    <measurement group_id="O2" value="10.63" spread="11.634"/>
                    <measurement group_id="O3" value="11.03" spread="15.467"/>
                    <measurement group_id="O4" value="-12.26" spread="7.082"/>
                    <measurement group_id="O5" value="-1.89" spread="16.512"/>
                    <measurement group_id="O6" value="3.98" spread="16.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>aPTT, Change at Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.50" spread="10.907"/>
                    <measurement group_id="O2" value="12.50" spread="15.303"/>
                    <measurement group_id="O3" value="1.20" spread="20.075"/>
                    <measurement group_id="O4" value="-10.26" spread="6.757"/>
                    <measurement group_id="O5" value="-0.38" spread="13.457"/>
                    <measurement group_id="O6" value="2.96" spread="15.825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>aPTT, Change at Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.79" spread="10.799"/>
                    <measurement group_id="O2" value="12.15" spread="15.232"/>
                    <measurement group_id="O3" value="4.50" spread="9.765"/>
                    <measurement group_id="O4" value="-11.77" spread="11.247"/>
                    <measurement group_id="O5" value="1.51" spread="17.381"/>
                    <measurement group_id="O6" value="4.65" spread="15.543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>aPTT, Change at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.42" spread="11.102"/>
                    <measurement group_id="O2" value="9.85" spread="15.999"/>
                    <measurement group_id="O3" value="10.13" spread="10.250"/>
                    <measurement group_id="O4" value="-12.87" spread="11.390"/>
                    <measurement group_id="O5" value="-0.74" spread="17.386"/>
                    <measurement group_id="O6" value="4.41" spread="16.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>aPTT, Change at Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.65" spread="13.378"/>
                    <measurement group_id="O2" value="14.25" spread="14.061"/>
                    <measurement group_id="O3" value="7.82" spread="11.580"/>
                    <measurement group_id="O4" value="-9.13" spread="8.390"/>
                    <measurement group_id="O5" value="2.26" spread="15.966"/>
                    <measurement group_id="O6" value="6.65" spread="14.817"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>aPTT, Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.00" spread="10.928"/>
                    <measurement group_id="O2" value="3.84" spread="18.089"/>
                    <measurement group_id="O3" value="7.68" spread="14.733"/>
                    <measurement group_id="O4" value="-7.57" spread="10.124"/>
                    <measurement group_id="O5" value="1.35" spread="13.278"/>
                    <measurement group_id="O6" value="3.45" spread="14.257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>aPTT, Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.46" spread="23.391"/>
                    <measurement group_id="O2" value="0.78" spread="16.332"/>
                    <measurement group_id="O3" value="-0.97" spread="26.633"/>
                    <measurement group_id="O4" value="9.37" spread="20.265"/>
                    <measurement group_id="O5" value="8.88" spread="21.093"/>
                    <measurement group_id="O6" value="5.05" spread="20.500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline for Fibrinogen by Dose Cohort</title>
        <description>Fibrinogen is a protein, specifically a clotting factor (factor I), that is essential for proper blood clot formation. Blood samples were obtained to evaluate the amount of fibrinogen.</description>
        <time_frame>Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.</time_frame>
        <population>This analysis population included all participants randomized and who had received at least 1 dose of randomized treatment. Number analyzed refers to number of participants evaluable for specified rows of time points.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
          <group group_id="O6">
            <title>Total</title>
            <description>The total group combined participants from all PF-06741086 cohorts in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline for Fibrinogen by Dose Cohort</title>
          <description>Fibrinogen is a protein, specifically a clotting factor (factor I), that is essential for proper blood clot formation. Blood samples were obtained to evaluate the amount of fibrinogen.</description>
          <population>This analysis population included all participants randomized and who had received at least 1 dose of randomized treatment. Number analyzed refers to number of participants evaluable for specified rows of time points.</population>
          <units>milligram/deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fibrinogen, Change at Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.7" spread="28.72"/>
                    <measurement group_id="O2" value="-59.7" spread="38.20"/>
                    <measurement group_id="O3" value="-3.5" spread="24.16"/>
                    <measurement group_id="O4" value="-54.4" spread="59.58"/>
                    <measurement group_id="O5" value="-52.1" spread="45.00"/>
                    <measurement group_id="O6" value="-42.6" spread="44.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibrinogen, Change at Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-59.4" spread="41.28"/>
                    <measurement group_id="O2" value="-51.0" spread="31.84"/>
                    <measurement group_id="O3" value="-8.3" spread="25.96"/>
                    <measurement group_id="O4" value="-85.6" spread="94.86"/>
                    <measurement group_id="O5" value="-72.5" spread="71.58"/>
                    <measurement group_id="O6" value="-52.7" spread="60.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibrinogen, Change at Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-72.0" spread="40.76"/>
                    <measurement group_id="O2" value="-36.8" spread="44.93"/>
                    <measurement group_id="O3" value="-33.2" spread="32.41"/>
                    <measurement group_id="O4" value="-87.9" spread="115.49"/>
                    <measurement group_id="O5" value="-79.9" spread="83.61"/>
                    <measurement group_id="O6" value="-59.2" spread="69.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibrinogen, Change at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-84.7" spread="43.53"/>
                    <measurement group_id="O2" value="-40.0" spread="26.57"/>
                    <measurement group_id="O3" value="-40.3" spread="20.99"/>
                    <measurement group_id="O4" value="-99.9" spread="106.59"/>
                    <measurement group_id="O5" value="-92.8" spread="80.82"/>
                    <measurement group_id="O6" value="-67.6" spread="65.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibrinogen, Change at Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.5" spread="85.81"/>
                    <measurement group_id="O2" value="10.0" spread="79.34"/>
                    <measurement group_id="O3" value="-21.3" spread="24.23"/>
                    <measurement group_id="O4" value="-58.7" spread="71.81"/>
                    <measurement group_id="O5" value="-46.1" spread="76.57"/>
                    <measurement group_id="O6" value="-25.9" spread="69.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibrinogen, Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.9" spread="47.93"/>
                    <measurement group_id="O2" value="-39.4" spread="63.27"/>
                    <measurement group_id="O3" value="-10.5" spread="44.94"/>
                    <measurement group_id="O4" value="-40.8" spread="74.28"/>
                    <measurement group_id="O5" value="-45.7" spread="58.91"/>
                    <measurement group_id="O6" value="-35.6" spread="56.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibrinogen, Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.6" spread="44.48"/>
                    <measurement group_id="O2" value="-5.2" spread="29.34"/>
                    <measurement group_id="O3" value="23.5" spread="26.80"/>
                    <measurement group_id="O4" value="-61.7" spread="126.18"/>
                    <measurement group_id="O5" value="-49.2" spread="88.13"/>
                    <measurement group_id="O6" value="-25.1" spread="73.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline for Antithrombin III by Dose Cohort</title>
        <description>Antithrombin (AT) is a protein produced by the liver that helps regulate blood clot formation (i.e., a naturally-occurring mild blood thinner). Blood samples were collected to measure the activity (function) and the amount (quantity) of antithrombin in an individual's blood is used to evaluate the person for excessive blood clotting.</description>
        <time_frame>Baseline, Study Day 8, 15, 22 and 29.</time_frame>
        <population>This analysis population included all participants randomized and who had received at least 1 dose of randomized treatment. Number analyzed refers to number of participants evaluable for specified rows of time points.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
          <group group_id="O6">
            <title>Total</title>
            <description>The total group combined participants from all PF-06741086 cohorts in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline for Antithrombin III by Dose Cohort</title>
          <description>Antithrombin (AT) is a protein produced by the liver that helps regulate blood clot formation (i.e., a naturally-occurring mild blood thinner). Blood samples were collected to measure the activity (function) and the amount (quantity) of antithrombin in an individual's blood is used to evaluate the person for excessive blood clotting.</description>
          <population>This analysis population included all participants randomized and who had received at least 1 dose of randomized treatment. Number analyzed refers to number of participants evaluable for specified rows of time points.</population>
          <units>Percentage of activity of AT in plasma</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Antithrombin III, Change at Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="5.18"/>
                    <measurement group_id="O2" value="-1.8" spread="7.05"/>
                    <measurement group_id="O3" value="3.7" spread="7.58"/>
                    <measurement group_id="O4" value="-7.3" spread="9.32"/>
                    <measurement group_id="O5" value="-2.6" spread="8.74"/>
                    <measurement group_id="O6" value="-1.0" spread="8.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antithrombin III, Change at Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="16.96"/>
                    <measurement group_id="O2" value="0.5" spread="8.14"/>
                    <measurement group_id="O3" value="-15.3" spread="16.45"/>
                    <measurement group_id="O4" value="-6.9" spread="6.74"/>
                    <measurement group_id="O5" value="-2.2" spread="13.30"/>
                    <measurement group_id="O6" value="-4.6" spread="14.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antithrombin III, Change at Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6" spread="17.55"/>
                    <measurement group_id="O2" value="5.2" spread="12.69"/>
                    <measurement group_id="O3" value="-5.3" spread="9.97"/>
                    <measurement group_id="O4" value="-4.4" spread="17.61"/>
                    <measurement group_id="O5" value="-6.0" spread="16.97"/>
                    <measurement group_id="O6" value="-3.3" spread="14.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antithrombin III, Change at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="8.04"/>
                    <measurement group_id="O2" value="-4.3" spread="11.55"/>
                    <measurement group_id="O3" value="-10.3" spread="15.45"/>
                    <measurement group_id="O4" value="-12.7" spread="12.96"/>
                    <measurement group_id="O5" value="-7.2" spread="12.20"/>
                    <measurement group_id="O6" value="-7.3" spread="12.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline for Troponin I by Dose Cohort</title>
        <description>Blood samples were collected to measure the level of cardiac-specific troponin I in the blood to help detect heart injury.</description>
        <time_frame>Baseline, Study Day 8, 15, 22, 29, 57 and 85.</time_frame>
        <population>This analysis population included all participants randomized and who had received at least 1 dose of randomized treatment. Number analyzed refers to number of participants evaluable for specified rows of time points.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
          <group group_id="O6">
            <title>Total</title>
            <description>The total group combined participants from all PF-06741086 cohorts in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline for Troponin I by Dose Cohort</title>
          <description>Blood samples were collected to measure the level of cardiac-specific troponin I in the blood to help detect heart injury.</description>
          <population>This analysis population included all participants randomized and who had received at least 1 dose of randomized treatment. Number analyzed refers to number of participants evaluable for specified rows of time points.</population>
          <units>nanogram/milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Troponin I, Change at Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Troponin I, Change at Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Troponin I, Change at Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0042" spread="0.01021"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0.0142" spread="0.03470"/>
                    <measurement group_id="O5" value="0.0092" spread="0.02494"/>
                    <measurement group_id="O6" value="0.0052" spread="0.01907"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Troponin I, Change at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0.0113" spread="0.02250"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0.0121" spread="0.03213"/>
                    <measurement group_id="O5" value="0.0065" spread="0.02357"/>
                    <measurement group_id="O6" value="0.0059" spread="0.02010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Troponin I, Change at Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Troponin I, Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vital Signs Data Meeting Pre-specified Criteria</title>
        <description>Criteria for potentially clinically important findings in vital signs data were defined as: 1) supine systolic blood pressure (BP): value &lt;90 mm Hg or change &gt;=30 mm Hg increase; 2) Supine diastolic BP: value &lt;50 mm Hg or change &gt;=20 mm Hg increase; 3) Supine pulse rate: value &lt;40 beats/min or &gt;120 beats/min.</description>
        <time_frame>Baseline to Study Day 113 Visit</time_frame>
        <population>This analysis population included all participants who received at least 1 dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
          <group group_id="O6">
            <title>Total</title>
            <description>The total group combined participants from all PF-06741086 cohorts in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Signs Data Meeting Pre-specified Criteria</title>
          <description>Criteria for potentially clinically important findings in vital signs data were defined as: 1) supine systolic blood pressure (BP): value &lt;90 mm Hg or change &gt;=30 mm Hg increase; 2) Supine diastolic BP: value &lt;50 mm Hg or change &gt;=20 mm Hg increase; 3) Supine pulse rate: value &lt;40 beats/min or &gt;120 beats/min.</description>
          <population>This analysis population included all participants who received at least 1 dose of investigational product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Supine systolic BP value &lt;90 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine systolic BP change &gt;=30 mm Hg increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine diastolic BP value &lt;50 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine diastolic BP change &gt;=20 mm Hg increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine pulse rate value &lt;40 beats/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine pulse rate value &gt;120 beats/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Electrocardiogram (ECG) Change Meeting Pre-specified Criteria</title>
        <description>Criteria for potentially clinically important changes in ECG were defined as: PR interval baseline &gt;200 msec and increase of &gt;=25%; PR interval baseline &lt;=200 msec and increase of &gt;=50%; QRS interval increase of &gt;=50%. Only the number of participants meeting pre-defined criteria was reported below.</description>
        <time_frame>Baseline to Study Day 29 Visit.</time_frame>
        <population>This analysis population included all participants who received at least 1 dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
          <group group_id="O6">
            <title>Total</title>
            <description>The total group combined participants from all PF-06741086 cohorts in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Electrocardiogram (ECG) Change Meeting Pre-specified Criteria</title>
          <description>Criteria for potentially clinically important changes in ECG were defined as: PR interval baseline &gt;200 msec and increase of &gt;=25%; PR interval baseline &lt;=200 msec and increase of &gt;=50%; QRS interval increase of &gt;=50%. Only the number of participants meeting pre-defined criteria was reported below.</description>
          <population>This analysis population included all participants who received at least 1 dose of investigational product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Changes in Physical Examination Findings</title>
        <description>Physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. Clinical significance was judged by the investigator.</description>
        <time_frame>Baseline to Study Day 113 Visit</time_frame>
        <population>This analysis population included all participants who received at least 1 dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
          <group group_id="O6">
            <title>Total</title>
            <description>The total group combined participants from all PF-06741086 cohorts in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Changes in Physical Examination Findings</title>
          <description>Physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. Clinical significance was judged by the investigator.</description>
          <population>This analysis population included all participants who received at least 1 dose of investigational product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Infusion and Injection Site Reactions</title>
        <description>Infusion and injection site reactions included: injection site bruising, injection site erythema, injection site haemorrhage, injection site induration, injection site pain, injection site pruritus, injection site swelling and injection site warmth. Grade of severity was defined as follows: Mild: Transient or mild discomfort (&lt; 48 hours); no medical intervention/therapy required. Moderate: Mild to moderate limitation in activity - some assistance may be needed; no or minimal medical intervention/therapy required. Severe: Marked limitation in activity, some assistance usually required; medical intervention/therapy required, hospitalizations possible.</description>
        <time_frame>Baseline to Study Day 113 Visit</time_frame>
        <population>This analysis population included all participants who received at least 1 dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
          <group group_id="O6">
            <title>Total</title>
            <description>The total group combined participants from all PF-06741086 cohorts in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Infusion and Injection Site Reactions</title>
          <description>Infusion and injection site reactions included: injection site bruising, injection site erythema, injection site haemorrhage, injection site induration, injection site pain, injection site pruritus, injection site swelling and injection site warmth. Grade of severity was defined as follows: Mild: Transient or mild discomfort (&lt; 48 hours); no medical intervention/therapy required. Moderate: Mild to moderate limitation in activity - some assistance may be needed; no or minimal medical intervention/therapy required. Severe: Marked limitation in activity, some assistance usually required; medical intervention/therapy required, hospitalizations possible.</description>
          <population>This analysis population included all participants who received at least 1 dose of investigational product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All-causality Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All-causality Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All-causality Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Bleeding Rate (ABR)</title>
        <description>Pre-treatment ABR = number of bleeding episodes within 6 months prior to study enrollment (total number of bleeding episodes in hemophilia history CRF) × 2; On-study ABR = number of bleeding episodes occurred within 9 days after the last dose / ([last dose date + 9 - first dose date + 1] / 365.25) The historical On Demand group was constructed using the following internal Pfizer studies: ReFacto AF 3082B2-4432 (B1831004), BeneFIX B1821010, and BeneFIX 3090A1-400 (B1821004). Participants who were on On Demand treatment in B1831004, as well as data from the On Demand period in B1821004 and B1821010 were used to construct the historical On Demand group. The resulting dataset were further filtered to match the key inclusion/exclusion criteria of Study B7841002 based on age and factor activity (18 &lt;=age &lt;=65 and factor activity &lt;=1%).</description>
        <time_frame>Pre-treatment: within 6 months prior to study enrollment; On-study: Day 1 to 9 days after the last dose (Day 78)</time_frame>
        <population>This efficacy analysis was conducted in the Per Protocol Analysis Set (PPAS) that included all participants who received at least 1 dose of investigational product and did not have any major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
          <group group_id="O6">
            <title>Total</title>
            <description>The total group combined participants from all PF-06741086 cohorts in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Bleeding Rate (ABR)</title>
          <description>Pre-treatment ABR = number of bleeding episodes within 6 months prior to study enrollment (total number of bleeding episodes in hemophilia history CRF) × 2; On-study ABR = number of bleeding episodes occurred within 9 days after the last dose / ([last dose date + 9 - first dose date + 1] / 365.25) The historical On Demand group was constructed using the following internal Pfizer studies: ReFacto AF 3082B2-4432 (B1831004), BeneFIX B1821010, and BeneFIX 3090A1-400 (B1821004). Participants who were on On Demand treatment in B1831004, as well as data from the On Demand period in B1821004 and B1821010 were used to construct the historical On Demand group. The resulting dataset were further filtered to match the key inclusion/exclusion criteria of Study B7841002 based on age and factor activity (18 &lt;=age &lt;=65 and factor activity &lt;=1%).</description>
          <population>This efficacy analysis was conducted in the Per Protocol Analysis Set (PPAS) that included all participants who received at least 1 dose of investigational product and did not have any major protocol deviations.</population>
          <units>Bleeding episodes per year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.00" spread="7.457"/>
                    <measurement group_id="O2" value="14.67" spread="1.633"/>
                    <measurement group_id="O3" value="20.33" spread="10.838"/>
                    <measurement group_id="O4" value="17.33" spread="3.011"/>
                    <measurement group_id="O5" value="20.17" spread="6.177"/>
                    <measurement group_id="O6" value="18.83" spread="7.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On-Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.22" spread="3.799"/>
                    <measurement group_id="O2" value="1.62" spread="2.533"/>
                    <measurement group_id="O3" value="4.17" spread="6.467"/>
                    <measurement group_id="O4" value="0.65" spread="1.603"/>
                    <measurement group_id="O5" value="2.43" spread="3.345"/>
                    <measurement group_id="O6" value="2.67" spread="4.092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The comparator was the Historical on Demand Group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Prophylactic treatment with PF-06741086 will be considered superior to On Demand treatment with respect to ABR reduction if 1) the upper limit of the 2-sided 80%CI of the ratio of ABR in PF/historical On Demand is &lt;1 and 2) the estimate of the ratio of ABR in PF/historical On Demand ≤0.3. Drug will be considered not superior to On Demand treatment if the lower limit of the 2-sided 80%CI of the ratio of PF/historical On Demand &gt;0.3.</non_inferiority_desc>
            <p_value>0.0002</p_value>
            <method>Negative Binomial Model</method>
            <param_type>ratio</param_type>
            <param_value>0.15</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>0.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The comparator was the Historical on Demand Group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Prophylactic treatment with PF-06741086 will be considered superior to On Demand treatment with respect to ABR reduction if 1) the upper limit of the 2-sided 80%CI of the ratio of ABR in PF/historical On Demand is &lt;1 and 2) the estimate of the ratio of ABR in PF/historical On Demand ≤0.3. Drug will be considered not superior to On Demand treatment if the lower limit of the 2-sided 80%CI of the ratio of PF/historical On Demand &gt;0.3.</non_inferiority_desc>
            <p_value>0.0001</p_value>
            <method>Negative Binomial Model</method>
            <param_type>ratio</param_type>
            <param_value>0.05</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The comparator was the Historical on Demand Group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Prophylactic treatment with PF-06741086 will be considered superior to On Demand treatment with respect to ABR reduction if 1) the upper limit of the 2-sided 80%CI of the ratio of ABR in PF/historical On Demand is &lt;1 and 2) the estimate of the ratio of ABR in PF/historical On Demand ≤0.3. Drug will be considered not superior to On Demand treatment if the lower limit of the 2-sided 80%CI of the ratio of PF/historical On Demand &gt;0.3.</non_inferiority_desc>
            <p_value>0.0002</p_value>
            <method>Negative Binomial Model</method>
            <param_type>ratio</param_type>
            <param_value>0.15</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>0.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The comparator was the Historical on Demand Group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Prophylactic treatment with PF-06741086 will be considered superior to On Demand treatment with respect to ABR reduction if 1) the upper limit of the 2-sided 80%CI of the ratio of ABR in PF/historical On Demand is &lt;1 and 2) the estimate of the ratio of ABR in PF/historical On Demand ≤0.3. Drug will be considered not superior to On Demand treatment if the lower limit of the 2-sided 80%CI of the ratio of PF/historical On Demand &gt;0.3.</non_inferiority_desc>
            <p_value>0.0005</p_value>
            <method>Negative Binomial Model</method>
            <param_type>ratio</param_type>
            <param_value>0.03</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The comparator was the Historical on Demand Group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Prophylactic treatment with PF-06741086 will be considered superior to On Demand treatment with respect to ABR reduction if 1) the upper limit of the 2-sided 80%CI of the ratio of ABR in PF/historical On Demand is &lt;1 and 2) the estimate of the ratio of ABR in PF/historical On Demand ≤0.3. Drug will be considered not superior to On Demand treatment if the lower limit of the 2-sided 80%CI of the ratio of PF/historical On Demand &gt;0.3.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Negative Binomial Model</method>
            <param_type>ratio</param_type>
            <param_value>0.09</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.05</ci_lower_limit>
            <ci_upper_limit>0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>On-Study versus Pre-Treatment</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Negative Binomial Model</method>
            <param_type>ratio</param_type>
            <param_value>0.18</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.11</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>On-Study versus Pre-Treatment</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Negative Binomial Model</method>
            <param_type>ratio</param_type>
            <param_value>0.10</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>On-Study versus Pre-Treatment</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0154</p_value>
            <method>Negative Binomial Model</method>
            <param_type>ratio</param_type>
            <param_value>0.20</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>0.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>On-Study versus Pre-Treatment</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Negative Binomial Model</method>
            <param_type>ratio</param_type>
            <param_value>0.04</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>On-Study versus Pre-Treatment</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Negative Binomial Model</method>
            <param_type>ratio</param_type>
            <param_value>0.12</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>0.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma PF-06741086 Concentrations</title>
        <description>Plasma PF-06741086 concentrations were analyzed using a validated, sensitive and specific electrochemiluminescence (ECL) method.</description>
        <time_frame>pre-dose on Study Day 1, 24hours (h), 72h post Study Day 1 dosing, pre-dose on Study Day 8, 15 and 22, pre-dose on Study Day 29, 24h, 96h post Study Day 29 dosing, pre-dose on Study Day 57, 168h, 840h post Study Day 57 dosing</time_frame>
        <population>The PK concentration population included all enrolled participants treated who had at least 1 quantifiable concentration. Number analyzed refers to number of participants evaluable for specified rows of categories.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma PF-06741086 Concentrations</title>
          <description>Plasma PF-06741086 concentrations were analyzed using a validated, sensitive and specific electrochemiluminescence (ECL) method.</description>
          <population>The PK concentration population included all enrolled participants treated who had at least 1 quantifiable concentration. Number analyzed refers to number of participants evaluable for specified rows of categories.</population>
          <units>nanogram/milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose on Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>24h post Day 1 dosing</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12180" spread="8500.2"/>
                    <measurement group_id="O2" value="15620" spread="8055.3"/>
                    <measurement group_id="O3" value="11640" spread="4670.6"/>
                    <measurement group_id="O4" value="18130" spread="9111.3"/>
                    <measurement group_id="O5" value="15150" spread="9011.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72h post Day 1 dosing</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17560" spread="10637"/>
                    <measurement group_id="O2" value="20850" spread="8433.7"/>
                    <measurement group_id="O3" value="24270" spread="8018.9"/>
                    <measurement group_id="O4" value="20640" spread="8978.4"/>
                    <measurement group_id="O5" value="19100" spread="9591.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose on Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11290" spread="10019"/>
                    <measurement group_id="O2" value="14060" spread="6201.2"/>
                    <measurement group_id="O3" value="16700" spread="5689.1"/>
                    <measurement group_id="O4" value="11940" spread="4981.7"/>
                    <measurement group_id="O5" value="11610" spread="7609.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose on Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22850" spread="15142"/>
                    <measurement group_id="O2" value="16680" spread="7668.8"/>
                    <measurement group_id="O3" value="28180" spread="10163"/>
                    <measurement group_id="O4" value="24870" spread="5726.8"/>
                    <measurement group_id="O5" value="23860" spread="11048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose on Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33010" spread="19724"/>
                    <measurement group_id="O2" value="17900" spread="10509"/>
                    <measurement group_id="O3" value="41200" spread="17504"/>
                    <measurement group_id="O4" value="36450" spread="10432"/>
                    <measurement group_id="O5" value="34600" spread="15590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose on Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46180" spread="21357"/>
                    <measurement group_id="O2" value="16780" spread="7939.7"/>
                    <measurement group_id="O3" value="59950" spread="30625"/>
                    <measurement group_id="O4" value="41500" spread="13884"/>
                    <measurement group_id="O5" value="43840" spread="17161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24h post Day 29 dosing</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66500" spread="27135"/>
                    <measurement group_id="O2" value="23530" spread="8548.4"/>
                    <measurement group_id="O3" value="73780" spread="22425"/>
                    <measurement group_id="O4" value="69920" spread="27902"/>
                    <measurement group_id="O5" value="68210" spread="26010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96h post Day 29 dosing</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69130" spread="30459"/>
                    <measurement group_id="O2" value="20680" spread="11580"/>
                    <measurement group_id="O3" value="74950" spread="27538"/>
                    <measurement group_id="O4" value="58150" spread="18753"/>
                    <measurement group_id="O5" value="62860" spread="22794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose on Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54580" spread="29022"/>
                    <measurement group_id="O2" value="18260" spread="15062"/>
                    <measurement group_id="O3" value="66480" spread="45529"/>
                    <measurement group_id="O4" value="59140" spread="24377"/>
                    <measurement group_id="O5" value="56860" spread="25382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>168h post Day 57 dosing</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53890" spread="43483"/>
                    <measurement group_id="O2" value="24800" spread="2994.4"/>
                    <measurement group_id="O3" value="87500" spread="37163"/>
                    <measurement group_id="O4" value="66700" spread="28971"/>
                    <measurement group_id="O5" value="60300" spread="35481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>840h post Day 57 dosing</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="586.6" spread="1318.4"/>
                    <measurement group_id="O4" value="90.00" spread="180.00"/>
                    <measurement group_id="O5" value="406.0" spread="1056.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PF-06741086</title>
        <description>AUClast was calculated by linear/Log trapezoidal method.</description>
        <time_frame>Pre-dose on Day 1, 24 and 96 hours post Day 1 dosing</time_frame>
        <population>The PK parameter analysis population included all enrolled participants treated who had at least 1 quantifiable concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PF-06741086</title>
          <description>AUClast was calculated by linear/Log trapezoidal method.</description>
          <population>The PK parameter analysis population included all enrolled participants treated who had at least 1 quantifiable concentration.</population>
          <units>nanogram*hour/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1818000" spread="79"/>
                    <measurement group_id="O2" value="2675000" spread="41"/>
                    <measurement group_id="O3" value="2806000" spread="37"/>
                    <measurement group_id="O4" value="2495000" spread="40"/>
                    <measurement group_id="O5" value="2130000" spread="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) of PF-06741086</title>
        <description>Cmax was observed directly from data.</description>
        <time_frame>Pre-dose on Day 1, 24 and 96 hours post Day 1 dosing, pre-dose on Day 29, 24 and 96 hours post Day 29 dosing</time_frame>
        <population>The PK parameter analysis population included all enrolled participants treated who had at least 1 quantifiable concentration. Number analyzed refers to number of participants evaluable for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of PF-06741086</title>
          <description>Cmax was observed directly from data.</description>
          <population>The PK parameter analysis population included all enrolled participants treated who had at least 1 quantifiable concentration. Number analyzed refers to number of participants evaluable for specified rows.</population>
          <units>nanogram/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14880" spread="70"/>
                    <measurement group_id="O2" value="19480" spread="42"/>
                    <measurement group_id="O3" value="23070" spread="37"/>
                    <measurement group_id="O4" value="19680" spread="51"/>
                    <measurement group_id="O5" value="17110" spread="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax, Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61850" spread="47"/>
                    <measurement group_id="O2" value="24150" spread="44"/>
                    <measurement group_id="O3" value="73490" spread="38"/>
                    <measurement group_id="O4" value="66070" spread="44"/>
                    <measurement group_id="O5" value="63930" spread="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lowest Concentration Observed During the Dosing Interval (Cmin) of PF-06741086</title>
        <description>Cmin was observed directly from data.</description>
        <time_frame>Pre-dose on Day 1, 24 and 96 hours post Day 1 dosing, pre-dose on Day 29, 24 and 96 hours post Day 29 dosing</time_frame>
        <population>The PK parameter analysis population included all enrolled participants treated who had at least 1 quantifiable concentration. Number analyzed refers to number of participants evaluable for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
        </group_list>
        <measure>
          <title>Lowest Concentration Observed During the Dosing Interval (Cmin) of PF-06741086</title>
          <description>Cmin was observed directly from data.</description>
          <population>The PK parameter analysis population included all enrolled participants treated who had at least 1 quantifiable concentration. Number analyzed refers to number of participants evaluable for specified rows.</population>
          <units>nanogram/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmin, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7980" spread="112"/>
                    <measurement group_id="O2" value="13040" spread="43"/>
                    <measurement group_id="O3" value="15660" spread="44"/>
                    <measurement group_id="O4" value="11140" spread="41"/>
                    <measurement group_id="O5" value="9429" spread="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin, Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42120" spread="52"/>
                    <measurement group_id="O2" value="15000" spread="59"/>
                    <measurement group_id="O3" value="53630" spread="61"/>
                    <measurement group_id="O4" value="39490" spread="37"/>
                    <measurement group_id="O5" value="40790" spread="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Plasma Concentration (Tmax) of PF-06741086</title>
        <description>Tmax was observed directly from data as time of first occurrence.</description>
        <time_frame>Pre-dose on Day 1, 24 and 96 hours post Day 1 dosing, pre-dose on Day 29, 24 and 96 hours post Day 29 dosing</time_frame>
        <population>The PK parameter analysis population included all enrolled participants treated who had at least 1 quantifiable concentration. Number analyzed refers to number of participants evaluable for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Plasma Concentration (Tmax) of PF-06741086</title>
          <description>Tmax was observed directly from data as time of first occurrence.</description>
          <population>The PK parameter analysis population included all enrolled participants treated who had at least 1 quantifiable concentration. Number analyzed refers to number of participants evaluable for specified rows.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" lower_limit="69.1" upper_limit="72.8"/>
                    <measurement group_id="O2" value="69.7" lower_limit="68.2" upper_limit="71.1"/>
                    <measurement group_id="O3" value="71.6" lower_limit="67.6" upper_limit="72.3"/>
                    <measurement group_id="O4" value="70.7" lower_limit="22.8" upper_limit="167"/>
                    <measurement group_id="O5" value="70.1" lower_limit="22.8" upper_limit="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax, Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7" lower_limit="23.1" upper_limit="94.2"/>
                    <measurement group_id="O2" value="23.7" lower_limit="22.0" upper_limit="71.7"/>
                    <measurement group_id="O3" value="58.5" lower_limit="23.3" upper_limit="97.0"/>
                    <measurement group_id="O4" value="22.8" lower_limit="22.1" upper_limit="94.7"/>
                    <measurement group_id="O5" value="23.3" lower_limit="22.1" upper_limit="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Serum Concentration-time Curve Over the Dosing Interval Tau (AUCtau) of PF-06741086</title>
        <description>The dosing interval tau was 1 week. AUCtau was obtained by linear/log trapezoidal method.</description>
        <time_frame>Pre-dose on Day 29, 24 and 96 hours post Day 29 dosing</time_frame>
        <population>The PK parameter analysis population included all enrolled participants treated who had at least 1 quantifiable concentration and in whom at least 1 of the PK parameters of interest was calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Serum Concentration-time Curve Over the Dosing Interval Tau (AUCtau) of PF-06741086</title>
          <description>The dosing interval tau was 1 week. AUCtau was obtained by linear/log trapezoidal method.</description>
          <population>The PK parameter analysis population included all enrolled participants treated who had at least 1 quantifiable concentration and in whom at least 1 of the PK parameters of interest was calculated.</population>
          <units>nanogram*hour/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9045000" spread="49"/>
                    <measurement group_id="O2" value="3309000" spread="50"/>
                    <measurement group_id="O3" value="11090000" spread="43"/>
                    <measurement group_id="O4" value="9248000" spread="38"/>
                    <measurement group_id="O5" value="9146000" spread="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Clearance After Oral Dose (CL/F) of PF-06741086</title>
        <description>CL/F was calculated by dose/AUCtau.</description>
        <time_frame>Pre-dose on Day 29, 24 and 96 hours post Day 29 dosing</time_frame>
        <population>The PK parameter analysis population included all enrolled participants treated who had at least 1 quantifiable concentration and in whom at least 1 of the PK parameters of interest was calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance After Oral Dose (CL/F) of PF-06741086</title>
          <description>CL/F was calculated by dose/AUCtau.</description>
          <population>The PK parameter analysis population included all enrolled participants treated who had at least 1 quantifiable concentration and in whom at least 1 of the PK parameters of interest was calculated.</population>
          <units>milliliter/hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.16" spread="49"/>
                    <measurement group_id="O2" value="45.34" spread="50"/>
                    <measurement group_id="O3" value="40.60" spread="43"/>
                    <measurement group_id="O4" value="32.43" spread="38"/>
                    <measurement group_id="O5" value="32.79" spread="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Tissue Factor Pathway Inhibitor (TFPI)</title>
        <description>Total amount of tissue factor pathway inhibitor (TFPI) (bound and unbound) in plasma. TFPI is a protease inhibitor which acts as an antagonist of the extrinsic coagulation pathway via inhibition of tissue factor activated coagulation factor VII (FVIIa) and activated factor X (FXa). Human plasma samples were analyzed for total TFPI concentrations using a validated, sensitive and specific high-performance liquid chromatography tandem mass spectrometric method (LC-MS/MS). Mixed model repeated measures (MMRM) was used to analyze the change from baseline on TFPI.</description>
        <time_frame>Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113</time_frame>
        <population>The analysis population included all enrolled participants who received at least 1 dose of study medication and had a baseline measurement and at least 1 post-dose measurement for at least 1 pharmacodynamic endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Tissue Factor Pathway Inhibitor (TFPI)</title>
          <description>Total amount of tissue factor pathway inhibitor (TFPI) (bound and unbound) in plasma. TFPI is a protease inhibitor which acts as an antagonist of the extrinsic coagulation pathway via inhibition of tissue factor activated coagulation factor VII (FVIIa) and activated factor X (FXa). Human plasma samples were analyzed for total TFPI concentrations using a validated, sensitive and specific high-performance liquid chromatography tandem mass spectrometric method (LC-MS/MS). Mixed model repeated measures (MMRM) was used to analyze the change from baseline on TFPI.</description>
          <population>The analysis population included all enrolled participants who received at least 1 dose of study medication and had a baseline measurement and at least 1 post-dose measurement for at least 1 pharmacodynamic endpoint.</population>
          <units>nanogram/milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TFPI, Change at Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="31.43"/>
                    <measurement group_id="O2" value="-13.4" spread="17.17"/>
                    <measurement group_id="O3" value="8.2" spread="19.83"/>
                    <measurement group_id="O4" value="0.4" spread="46.81"/>
                    <measurement group_id="O5" value="2.1" spread="38.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TFPI, Change at Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.4" spread="46.10"/>
                    <measurement group_id="O2" value="43.2" spread="25.76"/>
                    <measurement group_id="O3" value="74.0" spread="22.03"/>
                    <measurement group_id="O4" value="86.0" spread="29.71"/>
                    <measurement group_id="O5" value="62.7" spread="44.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TFPI, Change at Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7" spread="82.52"/>
                    <measurement group_id="O2" value="72.4" spread="10.81"/>
                    <measurement group_id="O3" value="120.5" spread="34.41"/>
                    <measurement group_id="O4" value="55.9" spread="69.84"/>
                    <measurement group_id="O5" value="49.3" spread="73.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TFPI, Change at Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.9" spread="107.56"/>
                    <measurement group_id="O2" value="78.8" spread="43.36"/>
                    <measurement group_id="O3" value="186.5" spread="52.80"/>
                    <measurement group_id="O4" value="156.1" spread="83.87"/>
                    <measurement group_id="O5" value="150.0" spread="92.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TFPI, Change at Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256.1" spread="137.09"/>
                    <measurement group_id="O2" value="110.0" spread="80.96"/>
                    <measurement group_id="O3" value="301.5" spread="84.39"/>
                    <measurement group_id="O4" value="223.3" spread="128.08"/>
                    <measurement group_id="O5" value="239.7" spread="128.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TFPI, Change at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324.2" spread="127.46"/>
                    <measurement group_id="O2" value="106.6" spread="77.56"/>
                    <measurement group_id="O3" value="334.7" spread="120.67"/>
                    <measurement group_id="O4" value="222.1" spread="135.29"/>
                    <measurement group_id="O5" value="269.2" spread="136.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TFPI, Change at Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="363.8" spread="156.87"/>
                    <measurement group_id="O2" value="115.6" spread="86.41"/>
                    <measurement group_id="O3" value="347.8" spread="170.70"/>
                    <measurement group_id="O4" value="286.7" spread="103.72"/>
                    <measurement group_id="O5" value="325.3" spread="133.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TFPI, Change at Day 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="337.7" spread="129.05"/>
                    <measurement group_id="O2" value="165.8" spread="35.20"/>
                    <measurement group_id="O3" value="351.0" spread="161.54"/>
                    <measurement group_id="O4" value="296.3" spread="112.30"/>
                    <measurement group_id="O5" value="317.0" spread="117.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TFPI, Change at Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="383.3" spread="137.17"/>
                    <measurement group_id="O2" value="140.0" spread="126.96"/>
                    <measurement group_id="O3" value="460.5" spread="247.37"/>
                    <measurement group_id="O4" value="371.0" spread="178.73"/>
                    <measurement group_id="O5" value="377.2" spread="152.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TFPI, Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="396.7" spread="216.54"/>
                    <measurement group_id="O2" value="246.7" spread="51.81"/>
                    <measurement group_id="O3" value="492.2" spread="308.46"/>
                    <measurement group_id="O4" value="425.0" spread="266.57"/>
                    <measurement group_id="O5" value="409.8" spread="230.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TFPI, Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" spread="72.30"/>
                    <measurement group_id="O2" value="41.5" spread="28.99"/>
                    <measurement group_id="O3" value="39.0" spread="16.15"/>
                    <measurement group_id="O4" value="-14.0" spread="33.17"/>
                    <measurement group_id="O5" value="9.7" spread="59.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Thrombin Generation (TGA) Lag Time</title>
        <description>An ex vivo pharmacodynamic measure of thrombin generation (initiation of thrombin generation), the lag time is the time needed to form the first traces of thrombin.</description>
        <time_frame>Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113</time_frame>
        <population>The analysis population included all enrolled participants who received at least 1 dose of study medication and had a baseline measurement and at least 1 post-dose measurement for at least 1 pharmacodynamic endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Thrombin Generation (TGA) Lag Time</title>
          <description>An ex vivo pharmacodynamic measure of thrombin generation (initiation of thrombin generation), the lag time is the time needed to form the first traces of thrombin.</description>
          <population>The analysis population included all enrolled participants who received at least 1 dose of study medication and had a baseline measurement and at least 1 post-dose measurement for at least 1 pharmacodynamic endpoint.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TGA lag time, Change at Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.16" spread="5.865"/>
                    <measurement group_id="O2" value="-2.77" spread="1.517"/>
                    <measurement group_id="O3" value="-3.93" spread="1.919"/>
                    <measurement group_id="O4" value="-4.13" spread="1.238"/>
                    <measurement group_id="O5" value="-5.64" spread="4.365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGA lag time, Change at Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.80" spread="6.079"/>
                    <measurement group_id="O2" value="-2.80" spread="1.399"/>
                    <measurement group_id="O3" value="-3.48" spread="1.957"/>
                    <measurement group_id="O4" value="-4.17" spread="1.501"/>
                    <measurement group_id="O5" value="-5.49" spread="4.467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGA lag time, Change at Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.94" spread="5.882"/>
                    <measurement group_id="O2" value="-2.88" spread="1.292"/>
                    <measurement group_id="O3" value="-3.57" spread="2.018"/>
                    <measurement group_id="O4" value="-4.43" spread="1.506"/>
                    <measurement group_id="O5" value="-5.69" spread="4.327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGA lag time, Change at Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.90" spread="5.897"/>
                    <measurement group_id="O2" value="-3.07" spread="1.221"/>
                    <measurement group_id="O3" value="-3.27" spread="1.870"/>
                    <measurement group_id="O4" value="-4.29" spread="1.342"/>
                    <measurement group_id="O5" value="-5.59" spread="4.327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGA lag time, Change at Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.94" spread="5.978"/>
                    <measurement group_id="O2" value="-2.80" spread="1.585"/>
                    <measurement group_id="O3" value="-3.12" spread="2.097"/>
                    <measurement group_id="O4" value="-4.34" spread="1.638"/>
                    <measurement group_id="O5" value="-5.64" spread="4.422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGA lag time, Change at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.33" spread="4.871"/>
                    <measurement group_id="O2" value="-2.77" spread="1.392"/>
                    <measurement group_id="O3" value="-3.43" spread="2.016"/>
                    <measurement group_id="O4" value="-4.32" spread="1.781"/>
                    <measurement group_id="O5" value="-4.83" spread="3.537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGA lag time, Change at Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.22" spread="4.893"/>
                    <measurement group_id="O2" value="-2.77" spread="1.372"/>
                    <measurement group_id="O3" value="-3.50" spread="2.082"/>
                    <measurement group_id="O4" value="-4.48" spread="1.681"/>
                    <measurement group_id="O5" value="-4.88" spread="3.640"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGA lag time, Change at Day 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.08" spread="4.414"/>
                    <measurement group_id="O2" value="-2.40" spread="1.568"/>
                    <measurement group_id="O3" value="-3.35" spread="2.261"/>
                    <measurement group_id="O4" value="-4.52" spread="1.771"/>
                    <measurement group_id="O5" value="-4.83" spread="3.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGA lag time, Change at Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.73" spread="4.711"/>
                    <measurement group_id="O2" value="-2.28" spread="2.020"/>
                    <measurement group_id="O3" value="-3.42" spread="1.962"/>
                    <measurement group_id="O4" value="-3.78" spread="1.376"/>
                    <measurement group_id="O5" value="-4.26" spread="3.346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGA lag time,Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.34" spread="5.745"/>
                    <measurement group_id="O2" value="-3.10" spread="1.344"/>
                    <measurement group_id="O3" value="-3.27" spread="2.014"/>
                    <measurement group_id="O4" value="-3.33" spread="1.755"/>
                    <measurement group_id="O5" value="-4.95" spread="4.497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGA lag time, Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="7.428"/>
                    <measurement group_id="O2" value="0.80" spread="0.283"/>
                    <measurement group_id="O3" value="1.53" spread="5.306"/>
                    <measurement group_id="O4" value="0.78" spread="5.251"/>
                    <measurement group_id="O5" value="-0.06" spread="6.304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Thrombin Generation (TGA) Peak</title>
        <description>An ex vivo pharmacodynamic measure of thrombin generation (initiation of thrombin generation). The peak represents the highest thrombin concentration that can be generated. There may be patients who reach the peak faster or slower than others and this may represent hyper- or hypocoagulability, respectively.</description>
        <time_frame>Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113</time_frame>
        <population>The analysis population included all enrolled participants who received at least 1 dose of study medication and had a baseline measurement and at least 1 post-dose measurement for at least 1 pharmacodynamic endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Thrombin Generation (TGA) Peak</title>
          <description>An ex vivo pharmacodynamic measure of thrombin generation (initiation of thrombin generation). The peak represents the highest thrombin concentration that can be generated. There may be patients who reach the peak faster or slower than others and this may represent hyper- or hypocoagulability, respectively.</description>
          <population>The analysis population included all enrolled participants who received at least 1 dose of study medication and had a baseline measurement and at least 1 post-dose measurement for at least 1 pharmacodynamic endpoint.</population>
          <units>nanomole</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TGA peak, Change at Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.93" spread="35.734"/>
                    <measurement group_id="O2" value="70.92" spread="23.721"/>
                    <measurement group_id="O3" value="68.18" spread="15.693"/>
                    <measurement group_id="O4" value="63.41" spread="9.743"/>
                    <measurement group_id="O5" value="68.17" spread="25.642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGA peak, Change at Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.00" spread="30.196"/>
                    <measurement group_id="O2" value="59.28" spread="30.156"/>
                    <measurement group_id="O3" value="50.87" spread="20.687"/>
                    <measurement group_id="O4" value="51.79" spread="14.929"/>
                    <measurement group_id="O5" value="55.89" spread="23.278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGA peak, Change at Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.36" spread="32.033"/>
                    <measurement group_id="O2" value="56.00" spread="33.636"/>
                    <measurement group_id="O3" value="50.30" spread="14.019"/>
                    <measurement group_id="O4" value="54.36" spread="15.007"/>
                    <measurement group_id="O5" value="51.86" spread="24.171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGA peak, Change at Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.01" spread="23.471"/>
                    <measurement group_id="O2" value="52.57" spread="28.440"/>
                    <measurement group_id="O3" value="46.40" spread="22.985"/>
                    <measurement group_id="O4" value="40.90" spread="7.886"/>
                    <measurement group_id="O5" value="44.96" spread="17.340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGA peak, Change at Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.50" spread="27.260"/>
                    <measurement group_id="O2" value="52.07" spread="33.558"/>
                    <measurement group_id="O3" value="38.15" spread="16.313"/>
                    <measurement group_id="O4" value="44.41" spread="22.567"/>
                    <measurement group_id="O5" value="44.46" spread="24.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGA peak, Change at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.95" spread="24.026"/>
                    <measurement group_id="O2" value="49.72" spread="29.316"/>
                    <measurement group_id="O3" value="38.23" spread="21.808"/>
                    <measurement group_id="O4" value="42.48" spread="23.057"/>
                    <measurement group_id="O5" value="42.72" spread="22.452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGA peak, Change at Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.93" spread="26.177"/>
                    <measurement group_id="O2" value="51.75" spread="29.276"/>
                    <measurement group_id="O3" value="37.72" spread="24.136"/>
                    <measurement group_id="O4" value="48.62" spread="21.427"/>
                    <measurement group_id="O5" value="41.70" spread="23.878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGA peak, Change at Day 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.68" spread="69.887"/>
                    <measurement group_id="O2" value="46.83" spread="37.084"/>
                    <measurement group_id="O3" value="36.25" spread="21.955"/>
                    <measurement group_id="O4" value="54.10" spread="28.276"/>
                    <measurement group_id="O5" value="66.42" spread="53.861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGA peak, Change at Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.13" spread="21.866"/>
                    <measurement group_id="O2" value="32.57" spread="20.368"/>
                    <measurement group_id="O3" value="34.67" spread="20.584"/>
                    <measurement group_id="O4" value="33.93" spread="7.688"/>
                    <measurement group_id="O5" value="35.53" spread="15.716"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGA peak, Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.60" spread="21.142"/>
                    <measurement group_id="O2" value="69.92" spread="40.250"/>
                    <measurement group_id="O3" value="30.15" spread="18.614"/>
                    <measurement group_id="O4" value="30.15" spread="22.743"/>
                    <measurement group_id="O5" value="34.16" spread="21.306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGA peak, Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.37" spread="33.703"/>
                    <measurement group_id="O2" value="16.05" spread="36.557"/>
                    <measurement group_id="O3" value="43.33" spread="68.794"/>
                    <measurement group_id="O4" value="6.93" spread="15.334"/>
                    <measurement group_id="O5" value="16.32" spread="27.345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Endogenous Thrombin Generation (TGA) Potential</title>
        <description>An ex vivo pharmacodynamic measure of thrombin generation. The endogenous TGA potential represents the total amount of active thrombin formed during thrombin generation and the peak height the maximal amount of thrombin formed.</description>
        <time_frame>Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113</time_frame>
        <population>The analysis population included all enrolled participants who received at least 1 dose of study medication and had a baseline measurement and at least 1 post-dose measurement for at least 1 pharmacodynamic endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Endogenous Thrombin Generation (TGA) Potential</title>
          <description>An ex vivo pharmacodynamic measure of thrombin generation. The endogenous TGA potential represents the total amount of active thrombin formed during thrombin generation and the peak height the maximal amount of thrombin formed.</description>
          <population>The analysis population included all enrolled participants who received at least 1 dose of study medication and had a baseline measurement and at least 1 post-dose measurement for at least 1 pharmacodynamic endpoint.</population>
          <units>nanomole*minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Endogenous TGA Potential, Change at Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="864.0" spread="250.60"/>
                    <measurement group_id="O2" value="816.8" spread="211.13"/>
                    <measurement group_id="O3" value="999.8" spread="249.59"/>
                    <measurement group_id="O4" value="1065.3" spread="161.71"/>
                    <measurement group_id="O5" value="964.6" spread="227.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endogenous TGA Potential, Change at Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="766.7" spread="236.94"/>
                    <measurement group_id="O2" value="714.8" spread="275.75"/>
                    <measurement group_id="O3" value="808.7" spread="288.78"/>
                    <measurement group_id="O4" value="825.1" spread="294.44"/>
                    <measurement group_id="O5" value="795.9" spread="258.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endogenous TGA Potential, Change at Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="691.9" spread="301.43"/>
                    <measurement group_id="O2" value="659.8" spread="295.11"/>
                    <measurement group_id="O3" value="796.5" spread="151.00"/>
                    <measurement group_id="O4" value="918.6" spread="276.26"/>
                    <measurement group_id="O5" value="805.2" spread="301.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endogenous TGA Potential, Change at Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="674.9" spread="244.61"/>
                    <measurement group_id="O2" value="608.5" spread="242.81"/>
                    <measurement group_id="O3" value="800.8" spread="334.99"/>
                    <measurement group_id="O4" value="639.3" spread="145.74"/>
                    <measurement group_id="O5" value="657.1" spread="194.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endogenous TGA Potential, Change at Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="646.9" spread="295.05"/>
                    <measurement group_id="O2" value="589.0" spread="274.33"/>
                    <measurement group_id="O3" value="647.0" spread="236.38"/>
                    <measurement group_id="O4" value="731.4" spread="302.89"/>
                    <measurement group_id="O5" value="689.1" spread="290.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endogenous TGA Potential, Change at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="588.2" spread="239.00"/>
                    <measurement group_id="O2" value="623.0" spread="188.84"/>
                    <measurement group_id="O3" value="618.3" spread="276.51"/>
                    <measurement group_id="O4" value="660.5" spread="340.36"/>
                    <measurement group_id="O5" value="624.3" spread="282.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endogenous TGA Potential, Change at Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="494.8" spread="247.86"/>
                    <measurement group_id="O2" value="672.0" spread="226.25"/>
                    <measurement group_id="O3" value="603.3" spread="332.44"/>
                    <measurement group_id="O4" value="710.2" spread="272.54"/>
                    <measurement group_id="O5" value="592.7" spread="270.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endogenous TGA Potential, Change at Day 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="716.5" spread="391.60"/>
                    <measurement group_id="O2" value="606.0" spread="280.39"/>
                    <measurement group_id="O3" value="583.7" spread="291.25"/>
                    <measurement group_id="O4" value="848.8" spread="387.17"/>
                    <measurement group_id="O5" value="776.6" spread="376.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endogenous TGA Potential, Change at Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="586.8" spread="200.04"/>
                    <measurement group_id="O2" value="445.2" spread="220.86"/>
                    <measurement group_id="O3" value="564.5" spread="287.43"/>
                    <measurement group_id="O4" value="579.7" spread="147.04"/>
                    <measurement group_id="O5" value="583.3" spread="167.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endogenous TGA Potential, Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="566.6" spread="202.22"/>
                    <measurement group_id="O2" value="812.2" spread="198.80"/>
                    <measurement group_id="O3" value="526.7" spread="297.03"/>
                    <measurement group_id="O4" value="493.7" spread="368.68"/>
                    <measurement group_id="O5" value="532.9" spread="280.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endogenous TGA Potential, Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256.4" spread="347.91"/>
                    <measurement group_id="O2" value="50.5" spread="290.62"/>
                    <measurement group_id="O3" value="306.5" spread="440.04"/>
                    <measurement group_id="O4" value="142.3" spread="361.25"/>
                    <measurement group_id="O5" value="203.8" spread="344.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Prothrombin Fragments 1 + 2</title>
        <description>An in vivo pharmacodynamic measure of thrombin generation (prothrombin cleavage). Prothrombin fragment 1+2 (F 1+2) is the amino terminus fragment of the prothrombin molecule. It is a polypeptide with a half-life of approximately 90 minutes. F 1+2 is released from prothrombin when prothrombin is converted to thrombin by the prothrombinase complex.</description>
        <time_frame>Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113</time_frame>
        <population>The analysis population included all enrolled participants who received at least 1 dose of study medication and had a baseline measurement and at least 1 post-dose measurement for at least 1 pharmacodynamic endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Prothrombin Fragments 1 + 2</title>
          <description>An in vivo pharmacodynamic measure of thrombin generation (prothrombin cleavage). Prothrombin fragment 1+2 (F 1+2) is the amino terminus fragment of the prothrombin molecule. It is a polypeptide with a half-life of approximately 90 minutes. F 1+2 is released from prothrombin when prothrombin is converted to thrombin by the prothrombinase complex.</description>
          <population>The analysis population included all enrolled participants who received at least 1 dose of study medication and had a baseline measurement and at least 1 post-dose measurement for at least 1 pharmacodynamic endpoint.</population>
          <units>picomole/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Prothrombin fragments 1 + 2, Change at Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="430.0" spread="383.03"/>
                    <measurement group_id="O2" value="498.3" spread="484.40"/>
                    <measurement group_id="O3" value="275.7" spread="206.71"/>
                    <measurement group_id="O4" value="438.9" spread="507.68"/>
                    <measurement group_id="O5" value="434.4" spread="432.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prothrombin fragments 1 + 2, Change at Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="548.1" spread="455.67"/>
                    <measurement group_id="O2" value="1096.7" spread="1403.57"/>
                    <measurement group_id="O3" value="574.5" spread="363.37"/>
                    <measurement group_id="O4" value="730.3" spread="537.21"/>
                    <measurement group_id="O5" value="639.2" spread="487.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prothrombin fragments 1 + 2, Change at Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="450.3" spread="396.09"/>
                    <measurement group_id="O2" value="562.2" spread="605.07"/>
                    <measurement group_id="O3" value="413.0" spread="171.50"/>
                    <measurement group_id="O4" value="580.7" spread="259.63"/>
                    <measurement group_id="O5" value="515.5" spread="328.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prothrombin fragments 1 + 2, Change at Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="481.7" spread="330.26"/>
                    <measurement group_id="O2" value="349.7" spread="212.59"/>
                    <measurement group_id="O3" value="389.2" spread="228.56"/>
                    <measurement group_id="O4" value="571.1" spread="474.23"/>
                    <measurement group_id="O5" value="526.4" spread="395.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prothrombin fragments 1 + 2, Change at Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="608.1" spread="336.97"/>
                    <measurement group_id="O2" value="322.3" spread="161.76"/>
                    <measurement group_id="O3" value="420.2" spread="166.66"/>
                    <measurement group_id="O4" value="524.1" spread="577.08"/>
                    <measurement group_id="O5" value="566.1" spread="456.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prothrombin fragments 1 + 2, Change at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="650.3" spread="415.58"/>
                    <measurement group_id="O2" value="288.0" spread="259.19"/>
                    <measurement group_id="O3" value="577.7" spread="302.76"/>
                    <measurement group_id="O4" value="429.3" spread="257.91"/>
                    <measurement group_id="O5" value="531.3" spread="344.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prothrombin fragments 1 + 2, Change at Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="655.7" spread="496.35"/>
                    <measurement group_id="O2" value="486.0" spread="608.26"/>
                    <measurement group_id="O3" value="521.0" spread="165.25"/>
                    <measurement group_id="O4" value="580.8" spread="507.83"/>
                    <measurement group_id="O5" value="618.3" spread="480.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prothrombin fragments 1 + 2, Change at Day 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="761.3" spread="509.02"/>
                    <measurement group_id="O2" value="642.5" spread="759.02"/>
                    <measurement group_id="O3" value="1527.7" spread="2499.96"/>
                    <measurement group_id="O4" value="609.2" spread="380.74"/>
                    <measurement group_id="O5" value="685.3" spread="435.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prothrombin fragments 1 + 2, Change at Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="586.5" spread="473.53"/>
                    <measurement group_id="O2" value="216.5" spread="173.44"/>
                    <measurement group_id="O3" value="465.3" spread="300.84"/>
                    <measurement group_id="O4" value="463.5" spread="397.57"/>
                    <measurement group_id="O5" value="525.0" spread="421.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prothrombin fragments 1 + 2, Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="588.3" spread="483.80"/>
                    <measurement group_id="O2" value="378.2" spread="207.16"/>
                    <measurement group_id="O3" value="470.2" spread="244.21"/>
                    <measurement group_id="O4" value="362.2" spread="378.54"/>
                    <measurement group_id="O5" value="483.9" spread="436.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prothrombin fragments 1 + 2, Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.6" spread="151.87"/>
                    <measurement group_id="O2" value="16.5" spread="19.09"/>
                    <measurement group_id="O3" value="-75.5" spread="76.86"/>
                    <measurement group_id="O4" value="-58.2" spread="121.15"/>
                    <measurement group_id="O5" value="-30.4" spread="135.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in D-Dimer</title>
        <description>An in vivo pharmacodynamic measure of thrombin generation (fibrin degradation). D-dimer is a fibrin degradation product, a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis. D-dimer is one of the protein fragments produced when a blood clot gets dissolved in the body. It is normally undetectable or detectable at a very low level unless the body is forming and breaking down blood clots. Then, its level in the blood can significantly rise.</description>
        <time_frame>Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113</time_frame>
        <population>The analysis population included all enrolled participants who received at least 1 dose of study medication and had a baseline measurement and at least 1 post-dose measurement for at least 1 pharmacodynamic endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in D-Dimer</title>
          <description>An in vivo pharmacodynamic measure of thrombin generation (fibrin degradation). D-dimer is a fibrin degradation product, a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis. D-dimer is one of the protein fragments produced when a blood clot gets dissolved in the body. It is normally undetectable or detectable at a very low level unless the body is forming and breaking down blood clots. Then, its level in the blood can significantly rise.</description>
          <population>The analysis population included all enrolled participants who received at least 1 dose of study medication and had a baseline measurement and at least 1 post-dose measurement for at least 1 pharmacodynamic endpoint.</population>
          <units>microgram/milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D-dimer, Change at Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0393" spread="0.16303"/>
                    <measurement group_id="O2" value="0.0792" spread="0.22238"/>
                    <measurement group_id="O3" value="0.1900" spread="0.09301"/>
                    <measurement group_id="O4" value="0.1086" spread="0.30536"/>
                    <measurement group_id="O5" value="0.0739" spread="0.23790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D-dimer, Change at Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2050" spread="0.24491"/>
                    <measurement group_id="O2" value="0.2842" spread="0.36896"/>
                    <measurement group_id="O3" value="0.3217" spread="0.23248"/>
                    <measurement group_id="O4" value="0.6729" spread="0.62524"/>
                    <measurement group_id="O5" value="0.4389" spread="0.51676"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D-dimer, Change at Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0743" spread="0.26111"/>
                    <measurement group_id="O2" value="0.2017" spread="0.29753"/>
                    <measurement group_id="O3" value="0.3292" spread="0.40635"/>
                    <measurement group_id="O4" value="0.5614" spread="0.54901"/>
                    <measurement group_id="O5" value="0.3179" spread="0.48422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D-dimer, Change at Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0979" spread="0.25666"/>
                    <measurement group_id="O2" value="0.1942" spread="0.28748"/>
                    <measurement group_id="O3" value="0.2500" spread="0.23424"/>
                    <measurement group_id="O4" value="0.1900" spread="0.82310"/>
                    <measurement group_id="O5" value="0.1439" spread="0.58769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D-dimer, Change at Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1364" spread="0.27802"/>
                    <measurement group_id="O2" value="0.2167" spread="0.33877"/>
                    <measurement group_id="O3" value="0.2000" spread="0.26109"/>
                    <measurement group_id="O4" value="0.1829" spread="1.27802"/>
                    <measurement group_id="O5" value="0.1596" spread="0.88887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D-dimer, Change at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0633" spread="0.20029"/>
                    <measurement group_id="O2" value="0.2308" spread="0.32355"/>
                    <measurement group_id="O3" value="0.1517" spread="0.42347"/>
                    <measurement group_id="O4" value="-0.0129" spread="1.17491"/>
                    <measurement group_id="O5" value="0.0223" spread="0.84172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D-dimer, Change at Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1350" spread="0.32388"/>
                    <measurement group_id="O2" value="0.1492" spread="0.26345"/>
                    <measurement group_id="O3" value="0.2133" spread="0.33914"/>
                    <measurement group_id="O4" value="-0.0833" spread="1.31549"/>
                    <measurement group_id="O5" value="0.0258" spread="0.92048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D-dimer, Change at Day 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0800" spread="0.28796"/>
                    <measurement group_id="O2" value="0.1283" spread="0.37519"/>
                    <measurement group_id="O3" value="0.1233" spread="0.49855"/>
                    <measurement group_id="O4" value="-0.1700" spread="1.68635"/>
                    <measurement group_id="O5" value="-0.0450" spread="1.16076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D-dimer, Change at Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1942" spread="0.30049"/>
                    <measurement group_id="O2" value="0.2175" spread="0.22554"/>
                    <measurement group_id="O3" value="0.1233" spread="0.36122"/>
                    <measurement group_id="O4" value="0.4033" spread="0.37120"/>
                    <measurement group_id="O5" value="0.2988" spread="0.34001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D-dimer, Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1664" spread="0.30521"/>
                    <measurement group_id="O2" value="0.5860" spread="1.00003"/>
                    <measurement group_id="O3" value="0.1833" spread="0.43840"/>
                    <measurement group_id="O4" value="0.2300" spread="0.60395"/>
                    <measurement group_id="O5" value="0.1958" spread="0.44682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D-dimer, Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1000" spread="0.22127"/>
                    <measurement group_id="O2" value="0.1875" spread="0.26517"/>
                    <measurement group_id="O3" value="0.0175" spread="0.41838"/>
                    <measurement group_id="O4" value="-0.7833" spread="1.60090"/>
                    <measurement group_id="O5" value="-0.4154" spread="1.10366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Dilute Prothrombin Time</title>
        <description>An ex vivo pharmacodynamic measure of thrombin generation (via extrinsic pathway). Clotting time is measured using a dilute prothrombin time reagent consisting of a unique formulation of relipidated recombinant tissue factor and calcium.</description>
        <time_frame>Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113</time_frame>
        <population>The analysis population included all enrolled participants who received at least 1 dose of study medication and had a baseline measurement and at least 1 post-dose measurement for at least 1 pharmacodynamic endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Dilute Prothrombin Time</title>
          <description>An ex vivo pharmacodynamic measure of thrombin generation (via extrinsic pathway). Clotting time is measured using a dilute prothrombin time reagent consisting of a unique formulation of relipidated recombinant tissue factor and calcium.</description>
          <population>The analysis population included all enrolled participants who received at least 1 dose of study medication and had a baseline measurement and at least 1 post-dose measurement for at least 1 pharmacodynamic endpoint.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dilute prothrombin Time, Change at Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.84" spread="21.023"/>
                    <measurement group_id="O2" value="-13.32" spread="25.780"/>
                    <measurement group_id="O3" value="-31.25" spread="13.606"/>
                    <measurement group_id="O4" value="-17.14" spread="26.167"/>
                    <measurement group_id="O5" value="-22.49" spread="23.470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dilute prothrombin Time, Change at Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.03" spread="24.312"/>
                    <measurement group_id="O2" value="-17.87" spread="20.042"/>
                    <measurement group_id="O3" value="-34.50" spread="18.306"/>
                    <measurement group_id="O4" value="-14.70" spread="30.971"/>
                    <measurement group_id="O5" value="-22.36" spread="27.907"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dilute prothrombin Time, Change at Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.63" spread="19.991"/>
                    <measurement group_id="O2" value="-15.10" spread="22.129"/>
                    <measurement group_id="O3" value="-31.23" spread="19.645"/>
                    <measurement group_id="O4" value="-20.97" spread="33.969"/>
                    <measurement group_id="O5" value="-22.30" spread="26.813"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dilute prothrombin Time, Change at Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.73" spread="23.070"/>
                    <measurement group_id="O2" value="-19.33" spread="20.853"/>
                    <measurement group_id="O3" value="-33.53" spread="14.880"/>
                    <measurement group_id="O4" value="1.11" spread="27.208"/>
                    <measurement group_id="O5" value="-9.81" spread="26.753"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dilute prothrombin Time, Change at Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.40" spread="22.351"/>
                    <measurement group_id="O2" value="-10.55" spread="16.057"/>
                    <measurement group_id="O3" value="-26.78" spread="32.501"/>
                    <measurement group_id="O4" value="-21.61" spread="30.842"/>
                    <measurement group_id="O5" value="-21.51" spread="25.877"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dilute prothrombin Time, Change at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.32" spread="13.867"/>
                    <measurement group_id="O2" value="-7.10" spread="20.643"/>
                    <measurement group_id="O3" value="-40.40" spread="22.458"/>
                    <measurement group_id="O4" value="-18.03" spread="24.600"/>
                    <measurement group_id="O5" value="-16.78" spread="19.613"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dilute prothrombin Time, Change at Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.27" spread="13.399"/>
                    <measurement group_id="O2" value="-23.45" spread="19.413"/>
                    <measurement group_id="O3" value="-45.18" spread="21.372"/>
                    <measurement group_id="O4" value="-17.47" spread="25.729"/>
                    <measurement group_id="O5" value="-15.37" spread="19.680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dilute prothrombin Time, Change at Day 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.35" spread="17.690"/>
                    <measurement group_id="O2" value="-21.23" spread="20.010"/>
                    <measurement group_id="O3" value="-29.10" spread="20.783"/>
                    <measurement group_id="O4" value="-19.97" spread="19.297"/>
                    <measurement group_id="O5" value="-21.66" spread="17.737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dilute prothrombin Time, Change at Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.75" spread="14.393"/>
                    <measurement group_id="O2" value="-12.03" spread="30.806"/>
                    <measurement group_id="O3" value="-26.80" spread="12.911"/>
                    <measurement group_id="O4" value="-11.72" spread="42.872"/>
                    <measurement group_id="O5" value="-13.23" spread="30.531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dilute prothrombin TIme, Change at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.99" spread="25.424"/>
                    <measurement group_id="O2" value="-25.80" spread="24.334"/>
                    <measurement group_id="O3" value="-23.43" spread="26.166"/>
                    <measurement group_id="O4" value="-12.42" spread="34.871"/>
                    <measurement group_id="O5" value="-17.03" spread="29.148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dilute prothrombin Time, Change at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.44" spread="13.578"/>
                    <measurement group_id="O2" value="14.30" spread="61.235"/>
                    <measurement group_id="O3" value="-39.63" spread="20.182"/>
                    <measurement group_id="O4" value="-12.78" spread="28.226"/>
                    <measurement group_id="O5" value="-14.75" spread="20.682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Tested Positive for Anti-PF-06741086 Antibody (ADA)</title>
        <description>Human plasma ADA samples were analyzed for the detection of anti PF-06741086 antibodies by using semi-quantitative electrochemiluminescence (ECL) method. The criterion for positive result of ADA samples was ADA titer &gt;=1.53. Treatment induced are negative prior to dosing and become positive during/after dosing. Treatment boosted are positive prior to dosing but titer increases during/after dosing.</description>
        <time_frame>Baseline up to Study Day 113</time_frame>
        <population>This analysis population included all participants who received at least 1 dose of investigational drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
          <group group_id="O6">
            <title>Total</title>
            <description>The total group combined participants from all PF-06741086 cohorts in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Tested Positive for Anti-PF-06741086 Antibody (ADA)</title>
          <description>Human plasma ADA samples were analyzed for the detection of anti PF-06741086 antibodies by using semi-quantitative electrochemiluminescence (ECL) method. The criterion for positive result of ADA samples was ADA titer &gt;=1.53. Treatment induced are negative prior to dosing and become positive during/after dosing. Treatment boosted are positive prior to dosing but titer increases during/after dosing.</description>
          <population>This analysis population included all participants who received at least 1 dose of investigational drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADA incidence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with treatment induced ADA incidence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with treatment boosted ADA incidence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Tested Positive for Neutralizing Antibody (NAb)</title>
        <description>Human plasma NAb samples were analyzed for the presence or absence of NAb to PF-06741086 using semi-quantitative electrochemiluminescence (ECL) method. Treatment induced are negative prior to dosing and become positive during/after dosing. Treatment boosted are positive prior to dosing but titer increases during/after dosing.</description>
        <time_frame>Baseline up to Study Day 113</time_frame>
        <population>Only positive ADA samples and the corresponding baseline sample were tested in the NAb assay.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O2">
            <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
          </group>
          <group group_id="O3">
            <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
            <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O4">
            <title>PF-06741086 300 mg SC QW Inhibitor</title>
            <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
          </group>
          <group group_id="O5">
            <title>Overall PF-06741086 300 mg SC</title>
            <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
          </group>
          <group group_id="O6">
            <title>Total</title>
            <description>The total group combined participants from all PF-06741086 cohorts in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Tested Positive for Neutralizing Antibody (NAb)</title>
          <description>Human plasma NAb samples were analyzed for the presence or absence of NAb to PF-06741086 using semi-quantitative electrochemiluminescence (ECL) method. Treatment induced are negative prior to dosing and become positive during/after dosing. Treatment boosted are positive prior to dosing but titer increases during/after dosing.</description>
          <population>Only positive ADA samples and the corresponding baseline sample were tested in the NAb assay.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NAb incidence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with treatment induced NAb incidence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with treatment boosted NAb incidence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>113 days</time_frame>
      <desc>The same event may appear as both an AE and an SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another participant, or one participant may have experienced both a serious and non-serious event during the study. Total number at risk below refers to the number of participants evaluable for SAEs or AEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>PF-06741086 300 mg SC QW Non-Inhibitor</title>
          <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
        </group>
        <group group_id="E2">
          <title>PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor</title>
          <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg loading dose on Day 1 and 150 mg subcutaneously (SC) once weekly (QW) from Day 8 to Day 78.</description>
        </group>
        <group group_id="E3">
          <title>PF-06741086 450 mg SC QW Non-Inhibitor</title>
          <description>Participants without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 450 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
        </group>
        <group group_id="E4">
          <title>PF-06741086 300 mg SC QW Inhibitor</title>
          <description>Participants with inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in this cohort received PF-06741086 300 mg subcutaneously (SC) once weekly (QW) from Day 1 to Day 78.</description>
        </group>
        <group group_id="E5">
          <title>Overall PF-06741086 300 mg SC</title>
          <description>The overall PF-06741086 300 mg SC group combined participants from both the PF-06741086 300 mg SC QW non-inhibitor and inhibitor dose cohorts.</description>
        </group>
        <group group_id="E6">
          <title>Total</title>
          <description>The total group combined participants from all PF-06741086 cohorts in this study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA21.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Tooth socket haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Physical assault</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA21.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="9" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Occupational exposure to product</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood fibrinogen decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Fibrin D dimer increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Prothrombin time prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Troponin I increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Haemophilic arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrospinal fluid leakage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02974855
org study id: B7841002
secondary id: 2016-001885-27
nct id: NCT02974855
lead sponsor: 
has dmc: No
is fda regulated drug: Yes
is fda regulated device: No
This study is designed to evaluate the safety, tolerability, pharmacokinetics,
      pharmacodynamics and efficacy of multiple subcutaneous and/or intravenous doses of
      PF-06741086 in subjects with severe hemophilia.
allocation: Non-Randomized
intervention model: Sequential Assignment
primary purpose: Prevention
masking: None (Open Label)
measure: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
time frame: Study Day 1 to Day 113 Visit
description: An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. AEs included both SAEs and non-serious AEs. TEAEs were AEs occurred following the start of treatment or AEs increasing in severity during treatment. Severe TEAEs were TEAEs that interfered significantly with participants' usual function. Treatment-related TEAEs were determined by the investigator.
measure: Number of Participants Discontinued From Study Due to TEAEs
time frame: Study Day 1 to Day 113 Visit
description: An AE was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.
measure: Number of Participants With Abnormal Laboratory Findings-Hematology
time frame: Baseline to Study Day 113 Visit
description: Hematology evaluation included: hemoglobin, hematocrit, erythrocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes. Predefined criteria for hemoglobin and hematocrit: <0.8*lower limit of normal (LLN) or <0.8*Baseline(Baseline <1.0*LLN); for platelets: <100,000*10^3/mm^3 or <= 0.77*Baseline (Baseline <1.0*LLN).
measure: Number of Participants With Abnormal Laboratory Findings-Clinical Chemistry
time frame: Baseline to Study Day 113
description: Clinical chemistry evaluation included bilirubin, direct and indirect bilirubin, aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, alkaline phosphatase, protein, albumin, urea nitrogen, creatinine, urate, triglycerides, sodium, potassium, chloride, calcium, bicarbonate, glucose, creatine kinase, troponin I, cholesterol and fibrinogen.
measure: Number of Participants With Abnormal Laboratory Findings-Urinalysis
time frame: Baseline to Study Day 113 Visit
description: Urinalysis included: pH, urine glucose, ketones, urine protein, urine hemoglobin, urobilinogen, urine bilirubin, nitrite, leukocyte esterase, urine erythrocytes, urine leukocytes and bacteria.
measure: Change From Baseline for Globulin by Dose Cohort
time frame: Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.
description: Blood samples were obtained to determine globulin level in serum, total globulin was derived as total protein other than albumin.
measure: Change From Baseline for Prothrombin International Normalized Ratio (PT/INR) by Dose Cohort
time frame: Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.
description: Blood samples were obtained to evaluate this ratio. The prothrombin time (PT) is a test that helps evaluate your ability to appropriately form blood clots. The international normalized ratio (INR) is a calculation based on results of a PT that is used to monitor individuals who are being treated with the blood-thinning medication (anticoagulant) warfarin (Coumadin®).
measure: Change From Baseline for Activated Partial Thromboplastin Time (aPTT) by Dose Cohort
time frame: Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.
description: The activated partial thromboplastin time (aPTT) is a screening test that helps evaluate a person's ability to appropriately form blood clots. It measures the number of seconds it takes for a clot to form in a sample of blood after substances (reagents) are added. Blood sample were obtained to evaluate aPTT.
measure: Change From Baseline for Fibrinogen by Dose Cohort
time frame: Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.
description: Fibrinogen is a protein, specifically a clotting factor (factor I), that is essential for proper blood clot formation. Blood samples were obtained to evaluate the amount of fibrinogen.
measure: Change From Baseline for Antithrombin III by Dose Cohort
time frame: Baseline, Study Day 8, 15, 22 and 29.
description: Antithrombin (AT) is a protein produced by the liver that helps regulate blood clot formation (i.e., a naturally-occurring mild blood thinner). Blood samples were collected to measure the activity (function) and the amount (quantity) of antithrombin in an individual's blood is used to evaluate the person for excessive blood clotting.
measure: Change From Baseline for Troponin I by Dose Cohort
time frame: Baseline, Study Day 8, 15, 22, 29, 57 and 85.
description: Blood samples were collected to measure the level of cardiac-specific troponin I in the blood to help detect heart injury.
measure: Number of Participants With Vital Signs Data Meeting Pre-specified Criteria
time frame: Baseline to Study Day 113 Visit
description: Criteria for potentially clinically important findings in vital signs data were defined as: 1) supine systolic blood pressure (BP): value <90 mm Hg or change >=30 mm Hg increase; 2) Supine diastolic BP: value <50 mm Hg or change >=20 mm Hg increase; 3) Supine pulse rate: value <40 beats/min or >120 beats/min.
measure: Number of Participants With Electrocardiogram (ECG) Change Meeting Pre-specified Criteria
time frame: Baseline to Study Day 29 Visit.
description: Criteria for potentially clinically important changes in ECG were defined as: PR interval baseline >200 msec and increase of >=25%; PR interval baseline <=200 msec and increase of >=50%; QRS interval increase of >=50%. Only the number of participants meeting pre-defined criteria was reported below.
measure: Number of Participants With Clinically Significant Changes in Physical Examination Findings
time frame: Baseline to Study Day 113 Visit
description: Physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. Clinical significance was judged by the investigator.
measure: Number of Participants With Infusion and Injection Site Reactions
time frame: Baseline to Study Day 113 Visit
description: Infusion and injection site reactions included: injection site bruising, injection site erythema, injection site haemorrhage, injection site induration, injection site pain, injection site pruritus, injection site swelling and injection site warmth. Grade of severity was defined as follows: Mild: Transient or mild discomfort (< 48 hours); no medical intervention/therapy required. Moderate: Mild to moderate limitation in activity - some assistance may be needed; no or minimal medical intervention/therapy required. Severe: Marked limitation in activity, some assistance usually required; medical intervention/therapy required, hospitalizations possible.
measure: Annualized Bleeding Rate (ABR)
time frame: Pre-treatment: within 6 months prior to study enrollment; On-study: Day 1 to 9 days after the last dose (Day 78)
description: Pre-treatment ABR = number of bleeding episodes within 6 months prior to study enrollment (total number of bleeding episodes in hemophilia history CRF) × 2; On-study ABR = number of bleeding episodes occurred within 9 days after the last dose / ([last dose date + 9 - first dose date + 1] / 365.25) The historical On Demand group was constructed using the following internal Pfizer studies: ReFacto AF 3082B2-4432 (B1831004), BeneFIX B1821010, and BeneFIX 3090A1-400 (B1821004). Participants who were on On Demand treatment in B1831004, as well as data from the On Demand period in B1821004 and B1821010 were used to construct the historical On Demand group. The resulting dataset were further filtered to match the key inclusion/exclusion criteria of Study B7841002 based on age and factor activity (18 <=age <=65 and factor activity <=1%).
measure: Plasma PF-06741086 Concentrations
time frame: pre-dose on Study Day 1, 24hours (h), 72h post Study Day 1 dosing, pre-dose on Study Day 8, 15 and 22, pre-dose on Study Day 29, 24h, 96h post Study Day 29 dosing, pre-dose on Study Day 57, 168h, 840h post Study Day 57 dosing
description: Plasma PF-06741086 concentrations were analyzed using a validated, sensitive and specific electrochemiluminescence (ECL) method.
measure: Area Under the Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PF-06741086
time frame: Pre-dose on Day 1, 24 and 96 hours post Day 1 dosing
description: AUClast was calculated by linear/Log trapezoidal method.
measure: Maximum Plasma Concentration (Cmax) of PF-06741086
time frame: Pre-dose on Day 1, 24 and 96 hours post Day 1 dosing, pre-dose on Day 29, 24 and 96 hours post Day 29 dosing
description: Cmax was observed directly from data.
measure: Lowest Concentration Observed During the Dosing Interval (Cmin) of PF-06741086
time frame: Pre-dose on Day 1, 24 and 96 hours post Day 1 dosing, pre-dose on Day 29, 24 and 96 hours post Day 29 dosing
description: Cmin was observed directly from data.
measure: Time to Reach Maximum Plasma Concentration (Tmax) of PF-06741086
time frame: Pre-dose on Day 1, 24 and 96 hours post Day 1 dosing, pre-dose on Day 29, 24 and 96 hours post Day 29 dosing
description: Tmax was observed directly from data as time of first occurrence.
measure: Area Under the Serum Concentration-time Curve Over the Dosing Interval Tau (AUCtau) of PF-06741086
time frame: Pre-dose on Day 29, 24 and 96 hours post Day 29 dosing
description: The dosing interval tau was 1 week. AUCtau was obtained by linear/log trapezoidal method.
measure: Apparent Clearance After Oral Dose (CL/F) of PF-06741086
time frame: Pre-dose on Day 29, 24 and 96 hours post Day 29 dosing
description: CL/F was calculated by dose/AUCtau.
measure: Change From Baseline in Total Tissue Factor Pathway Inhibitor (TFPI)
time frame: Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113
description: Total amount of tissue factor pathway inhibitor (TFPI) (bound and unbound) in plasma. TFPI is a protease inhibitor which acts as an antagonist of the extrinsic coagulation pathway via inhibition of tissue factor activated coagulation factor VII (FVIIa) and activated factor X (FXa). Human plasma samples were analyzed for total TFPI concentrations using a validated, sensitive and specific high-performance liquid chromatography tandem mass spectrometric method (LC-MS/MS). Mixed model repeated measures (MMRM) was used to analyze the change from baseline on TFPI.
measure: Change From Baseline in Thrombin Generation (TGA) Lag Time
time frame: Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113
description: An ex vivo pharmacodynamic measure of thrombin generation (initiation of thrombin generation), the lag time is the time needed to form the first traces of thrombin.
measure: Change From Baseline in Thrombin Generation (TGA) Peak
time frame: Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113
description: An ex vivo pharmacodynamic measure of thrombin generation (initiation of thrombin generation). The peak represents the highest thrombin concentration that can be generated. There may be patients who reach the peak faster or slower than others and this may represent hyper- or hypocoagulability, respectively.
measure: Change From Baseline in Endogenous Thrombin Generation (TGA) Potential
time frame: Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113
description: An ex vivo pharmacodynamic measure of thrombin generation. The endogenous TGA potential represents the total amount of active thrombin formed during thrombin generation and the peak height the maximal amount of thrombin formed.
measure: Change From Baseline in Prothrombin Fragments 1 + 2
time frame: Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113
description: An in vivo pharmacodynamic measure of thrombin generation (prothrombin cleavage). Prothrombin fragment 1+2 (F 1+2) is the amino terminus fragment of the prothrombin molecule. It is a polypeptide with a half-life of approximately 90 minutes. F 1+2 is released from prothrombin when prothrombin is converted to thrombin by the prothrombinase complex.
measure: Change From Baseline in D-Dimer
time frame: Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113
description: An in vivo pharmacodynamic measure of thrombin generation (fibrin degradation). D-dimer is a fibrin degradation product, a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis. D-dimer is one of the protein fragments produced when a blood clot gets dissolved in the body. It is normally undetectable or detectable at a very low level unless the body is forming and breaking down blood clots. Then, its level in the blood can significantly rise.
measure: Change From Baseline in Dilute Prothrombin Time
time frame: Baseline, Study Day 2, 4, 8, 15, 22, 29, 30, 33, 57, 85 and 113
description: An ex vivo pharmacodynamic measure of thrombin generation (via extrinsic pathway). Clotting time is measured using a dilute prothrombin time reagent consisting of a unique formulation of relipidated recombinant tissue factor and calcium.
measure: Number of Participants Who Tested Positive for Anti-PF-06741086 Antibody (ADA)
time frame: Baseline up to Study Day 113
description: Human plasma ADA samples were analyzed for the detection of anti PF-06741086 antibodies by using semi-quantitative electrochemiluminescence (ECL) method. The criterion for positive result of ADA samples was ADA titer >=1.53. Treatment induced are negative prior to dosing and become positive during/after dosing. Treatment boosted are positive prior to dosing but titer increases during/after dosing.
measure: Number of Participants Who Tested Positive for Neutralizing Antibody (NAb)
time frame: Baseline up to Study Day 113
description: Human plasma NAb samples were analyzed for the presence or absence of NAb to PF-06741086 using semi-quantitative electrochemiluminescence (ECL) method. Treatment induced are negative prior to dosing and become positive during/after dosing. Treatment boosted are positive prior to dosing but titer increases during/after dosing.
arm group label: PF-06741086 (Cohort 1)
arm group type: Experimental
arm group label: PF-06741086 (Cohort 2)
arm group type: Experimental
arm group label: PF-06741086 (Cohort 3)
arm group type: Experimental
arm group label: PF-06741086 (Cohort 4)
arm group type: Experimental
intervention type: Biological
intervention name: PF-06741086
description: PF-06741086 subcutaneous (SC) injection
arm group label: PF-06741086 (Cohort 1)
intervention type: Biological
intervention name: PF-06741086
description: PF-06741086 SC injection
arm group label: PF-06741086 (Cohort 2)
intervention type: Biological
intervention name: PF-06741086
description: PF-06741086 SC injection
arm group label: PF-06741086 (Cohort 3)
intervention type: Biological
intervention name: PF-06741086
description: PF-06741086 SC injection
arm group label: PF-06741086 (Cohort 4)
criteria: 
gender: Male
gender based: Yes
minimum age: 18 Years
maximum age: 64 Years
healthy volunteers: No
last name: Pfizer CT.gov Call Center
role: Study Director
affiliation: Pfizer
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: Chile
country: Croatia
country: Poland
country: South Africa
country: Switzerland
country: United States
country: France
country: Spain
url: https://pmiform.com/clinical-trial-info-request?StudyID=B7841002
description: To obtain contact information for a study center near you, click here.
responsible party type: Sponsor
mesh term: Hemophilia A
sharing ipd: Yes
ipd description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
ipd url: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests
provided document: 
provided document: 
participant flow: 
baseline: 
outcome list: 
reported events: 
certain agreements: 
point of contact: 